<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Neuropsychiatr Dis Treat</journal-id><journal-id journal-id-type="iso-abbrev">Neuropsychiatr Dis Treat</journal-id><journal-id journal-id-type="publisher-id">Neuropsychiatric Disease and
Treatment</journal-id><journal-title-group><journal-title>Neuropsychiatric Disease and Treatment</journal-title></journal-title-group><issn pub-type="ppub">1176-6328</issn><issn pub-type="epub">1178-2021</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27226715</article-id><article-id pub-id-type="pmc">4863687</article-id><article-id pub-id-type="doi">10.2147/NDT.S94158</article-id><article-id pub-id-type="publisher-id">ndt-12-1085</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Guanfacine extended release for children and adolescents with
attention-deficit/hyperactivity disorder: efficacy following prior methylphenidate
treatment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Huss</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="af1-ndt-12-1085">1</xref><xref ref-type="corresp" rid="c1-ndt-12-1085"/></contrib><contrib contrib-type="author"><name><surname>Sikirica</surname><given-names>Vanja</given-names></name><xref ref-type="aff" rid="af2-ndt-12-1085">2</xref></contrib><contrib contrib-type="author"><name><surname>Hervas</surname><given-names>Amaia</given-names></name><xref ref-type="aff" rid="af3-ndt-12-1085">3</xref><xref ref-type="aff" rid="af4-ndt-12-1085">4</xref></contrib><contrib contrib-type="author"><name><surname>Newcorn</surname><given-names>Jeffrey H</given-names></name><xref ref-type="aff" rid="af5-ndt-12-1085">5</xref></contrib><contrib contrib-type="author"><name><surname>Harpin</surname><given-names>Valerie</given-names></name><xref ref-type="aff" rid="af6-ndt-12-1085">6</xref></contrib><contrib contrib-type="author"><name><surname>Robertson</surname><given-names>Brigitte</given-names></name><xref ref-type="aff" rid="af7-ndt-12-1085">7</xref></contrib></contrib-group><aff id="af1-ndt-12-1085"><label>1</label>Child and Adolescent Psychiatry, Johannes Gutenberg University Mainz,
Mainz, Germany</aff><aff id="af2-ndt-12-1085"><label>2</label>Global Health Economics, Outcomes Research and Epidemiology, Shire,
Wayne, PA, USA</aff><aff id="af3-ndt-12-1085"><label>3</label>Child and Adolescent Mental Health Unit, University Hospital
M&#x000fa;tua de Terressa, Barcelona, Spain</aff><aff id="af4-ndt-12-1085"><label>4</label>Developmental Disorders Unit (UETD), Hospital San Juan de Dios,
Barcelona, Spain</aff><aff id="af5-ndt-12-1085"><label>5</label>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New
York, NY, USA</aff><aff id="af6-ndt-12-1085"><label>6</label>Ryegate Children&#x02019;s Centre, Sheffield Children&#x02019;s NHS
Foundation Trust, Sheffield, UK</aff><aff id="af7-ndt-12-1085"><label>7</label>Global Clinical Development, Shire, Wayne, PA, USA</aff><author-notes><corresp id="c1-ndt-12-1085">Correspondence: Michael Huss, Child and Adolescent
Psychiatry, Johannes Gutenberg University Mainz, Langenbeckstrasse 1, 55131 Mainz,
Germany, Tel +49 6131 378 2300, Fax +49 6131 378 2830, Email
<email>m.huss@rfk.landeskrankenhaus.de</email></corresp></author-notes><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>05</day><month>5</month><year>2016</year></pub-date><volume>12</volume><fpage>1085</fpage><lpage>1101</lpage><permissions><copyright-statement>&#x000a9; 2016 Huss et al. This work is published by Dove Medical
Press Limited, and licensed under Creative Commons Attribution &#x02013; Non Commercial
(unported, v3.0) License</copyright-statement><copyright-year>2016</copyright-year><license><license-p>The full terms of the License are available at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>. Non-commercial uses of
the work are permitted without any further permission from Dove Medical Press
Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><p>Guanfacine extended release (GXR) and atomoxetine (ATX) are nonstimulant treatments
for attention-deficit/hyperactivity disorder (ADHD). As nonstimulant treatments are
often used after stimulants in ADHD, GXR was assessed relative to prior stimulant
treatment in a randomized controlled trial (RCT), in which ATX was included as a
reference arm, and in the open-label phase of a randomized-withdrawal study (RWS).
Participants were 6&#x02013;17 years old with ADHD Rating Scale version IV
(ADHD-RS-IV) scores &#x02265;32 and Clinical Global Impressions &#x02013; Severity
scores &#x02265;4. RCT participants received dose-optimized GXR (1&#x02013;7 mg/day),
ATX (10&#x02013;100 mg/day), or placebo for 10&#x02013;13 weeks. RWS participants
received dose-optimized GXR (1&#x02013;7 mg/day) for 13 weeks. Participants&#x02019;
last stimulant medication prior to enrolment, and reasons for stopping this
medication, were collected at baseline. Change from baseline ADHD-RS-IV score and the
proportion of responders were assessed by prior stimulant exposure. Of 163 RCT and
296 RWS participants who had previously received stimulant treatment, 142 and 224,
respectively, had received methylphenidate (MPH); due to the low number of
participants and the heterogeneity of non-MPH treatments, we only report data for
prior MPH treatment. The most frequent reasons for stopping MPH were lack of
effectiveness or side effects. Placebo-adjusted ADHD-RS-IV changes from baseline were
significant in participants receiving GXR (prior MPH, &#x02212;9.8,
<italic>P</italic>&#x0003c;0.001, effect size [ES] 0.85;
stimulant-na&#x000ef;ve, &#x02212;7.6, <italic>P</italic>&#x0003c;0.001, ES 0.65). In
ATX-treated participants, significant placebo-adjusted differences were seen in
stimulant-na&#x000ef;ve (&#x02212;5.0, <italic>P</italic>=0.022, ES 0.43) but not
prior MPH-treated (&#x02212;1.8, <italic>P</italic>&#x0003e;0.05, ES 0.15)
participants. More participants met responder criteria with GXR versus placebo,
regardless of prior treatment. GXR response was unaffected by prior stimulant
treatment; ATX produced improvement only in stimulant-na&#x000ef;ve participants
relative to placebo. These findings may be relevant to clinical decision-making
regarding sequencing of ADHD treatments.</p></abstract><abstract abstract-type="graphical"><title>Video abstract</title><p>
<media xlink:href="ndt-12-1085-s.avi" xlink:type="simple" id="d36e158" position="anchor" mimetype="video"/></p></abstract><kwd-group><title>Keywords</title><kwd>ADHD</kwd><kwd>atomoxetine</kwd><kwd>GXR</kwd><kwd>inadequate responders</kwd><kwd>effectiveness</kwd><kwd>trial</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Although stimulant medications, such as methylphenidate (MPH), are the first-line
treatment for many individuals with attention-deficit/hyperactivity disorder
(ADHD),<xref rid="b1-ndt-12-1085" ref-type="bibr">1</xref>,<xref rid="b2-ndt-12-1085" ref-type="bibr">2</xref> non-stimulant medications, such as atomoxetine
(ATX)<xref rid="b3-ndt-12-1085" ref-type="bibr">3</xref> and a prolonged-release
formulation of guanfacine (guanfacine extended release [GXR]),<xref rid="b4-ndt-12-1085" ref-type="bibr">4</xref>,<xref rid="b5-ndt-12-1085" ref-type="bibr">5</xref> provide an alternative option for some patients with
ADHD when stimulant treatments are contraindicated or may not otherwise meet their
needs. In clinical studies, approximately 30% of participants have an inadequate
response to treatment with a single stimulant.<xref rid="b6-ndt-12-1085" ref-type="bibr">6</xref> Factors contributing to an inadequate response include suboptimal
inadequate dosing, dose-limiting side effects, and poor adherence. Also, patients or
their physicians may have a preference for nonstimulant medication.</p><p>Guanfacine is a selective &#x003b1;<sub>2A</sub>-adrenergic receptor agonist<xref rid="b7-ndt-12-1085" ref-type="bibr">7</xref>,<xref rid="b8-ndt-12-1085" ref-type="bibr">8</xref> with documented beneficial effects on prefrontal
cortical cognitive functions.<xref rid="b9-ndt-12-1085" ref-type="bibr">9</xref>&#x02013;<xref rid="b12-ndt-12-1085" ref-type="bibr">12</xref> Randomized
controlled trials (RCTs) in the US have shown GXR to be efficacious and well tolerated
as monotherapy or adjunctive therapy for ADHD.<xref rid="b4-ndt-12-1085" ref-type="bibr">4</xref>,<xref rid="b5-ndt-12-1085" ref-type="bibr">5</xref>,<xref rid="b13-ndt-12-1085" ref-type="bibr">13</xref> GXR is approved for the treatment of ADHD as
monotherapy or adjunctive to stimulant therapy for children and adolescents
(6&#x02013;17 years) in the US and Canada, and in Europe for children and adolescents
(6&#x02013;17 years) for whom stimulants are not suitable, not tolerated, or have been
shown to be ineffective.<xref rid="b14-ndt-12-1085" ref-type="bibr">14</xref> ATX is a
selective blocker of noradrenaline transporters,<xref rid="b15-ndt-12-1085" ref-type="bibr">15</xref> and is approved in the US and several European
countries as monotherapy for treatment of children aged 6 years and older, adolescents,
and adults with ADHD.<xref rid="b16-ndt-12-1085" ref-type="bibr">16</xref></p><p>As nonstimulant treatments are often used after stimulants in the treatment of ADHD, it
is important to understand how these medications perform following exposure to
stimulants. To date, however, there have been limited available data that directly
address this question. Findings from a large, placebo-controlled, double-blind study of
ATX versus MPH suggested that ATX was less effective in participants previously treated
with stimulants than those who were stimulant-na&#x000ef;ve.<xref rid="b17-ndt-12-1085" ref-type="bibr">17</xref> A recent meta-regression analysis supports this
finding, in that studies with a greater proportion of treatment-na&#x000ef;ve patients
were associated with a greater effect size (ES) for ATX compared with placebo.<xref rid="b18-ndt-12-1085" ref-type="bibr">18</xref> However, it is unknown whether lesser
response following prior stimulant treatment is specific to ATX or would extend to other
nonstimulants, such as guanfacine.</p><p>Here, we report data from two international Phase III trials on the efficacy of GXR,
analyzed according to prior stimulant treatment (prior stimulant treatment or
stimulant-na&#x000ef;ve). These analyses were prespecified as a separate analysis plan
to the main study outcomes. The first study was an RCT that assessed the efficacy and
safety of dose-optimized GXR compared with placebo in children/adolescents with ADHD in
Europe, the US, and Canada (NCT01244490).<xref rid="b19-ndt-12-1085" ref-type="bibr">19</xref> An ATX active reference arm was included to provide benchmark data for an
existing nonstimulant treatment. The second Phase III study was a randomized-withdrawal
study (RWS) designed to evaluate the long-term (6-month) maintenance of efficacy of GXR
in children/adolescents with ADHD in Europe, the US, and Canada who had responded to an
initial, short-term (13-week) open-label (OL) treatment phase (NCT01081145).<xref rid="b20-ndt-12-1085" ref-type="bibr">20</xref>,<xref rid="b21-ndt-12-1085" ref-type="bibr">21</xref> The current analyses utilized data from only the OL
phase of the RWS, and were included to provide cross-validation of the effects of GXR in
a larger data set than the RCT. The objective of these analyses was to assess whether
the effects of nonstimulant treatments were influenced by prior treatment with stimulant
medication.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><p>The study protocols, protocol amendments, protocol administrative changes, final
approved informed consent, assent documents, relevant supporting information, and all
types of participant-recruitment information were approved by the study centers&#x02019;
ethics committees and regulatory agencies (as appropriate) prior to study initiation
(protocol) or implementation (amendments). The studies were conducted in accordance with
International Conference on Harmonisation of Good Clinical Practice, the principles of
the <italic>Declaration of Helsinki</italic>, and other applicable local ethical and
legal requirements. Written informed consent was obtained from all participants or their
legally authorized representative before the performance of any study-specific
procedures.</p><sec sec-type="subjects"><title>Participants</title><p>Children and adolescents (6&#x02013;17 years old) with a diagnosis of ADHD (ADHD
Rating Scale version IV [ADHD-RS-IV] total score &#x02265;32) of at
least moderate severity (Clinical Global Impression &#x02013; Severity scale
[CGI&#x02013;S] score &#x02265;4) were enrolled in both studies. Full
inclusion and exclusion criteria have been reported elsewhere.<xref rid="b19-ndt-12-1085" ref-type="bibr">19</xref>&#x02013;<xref rid="b21-ndt-12-1085" ref-type="bibr">21</xref> Briefly, participants with age-appropriate
intellectual functioning; blood pressure measurements within the 95th percentile for
age, sex, and height; and the ability to swallow tablets were eligible to
participate. Girls of childbearing potential underwent pregnancy tests at screening
and baseline, and had to comply with any protocol contraceptive requirements.
Exclusion criteria included clinically significant illness or current, controlled
(requiring a prohibited medication or behavior-modification program) or uncontrolled
comorbid psychiatric diagnosis (except oppositional defiant disorder);
history/presence of cardiac abnormalities (conduction or rhythm abnormalities,
bradycardia, exercise-related cardiac events, syncope); orthostatic hypotension or
hypertension; seizures; glaucoma; history of alcohol or substance abuse; and serious
tic disorder, including Tourette&#x02019;s syndrome. Participants who were currently
considered a suicide risk (investigator opinion), had previously made a suicide
attempt, or demonstrated prior or current active suicidal ideation were excluded.</p></sec><sec sec-type="methods"><title>Study designs</title><sec><title>RCT</title><p>The RCT was a double-blind, parallel-group, placebo-controlled study (NCT01244490;
EUdraCT 2010-018579-12) conducted at 58 centers in Europe, the US, and Canada
between January 2011 and May 2013.<xref rid="b19-ndt-12-1085" ref-type="bibr">19</xref> Participants were randomized at baseline (1:1:1) to treatment with
dose-optimized GXR (children [6&#x02013;12 years], 1&#x02013;4
mg/day; adolescents [13&#x02013;17 years], 1&#x02013;7 mg/day),
ATX (10&#x02013;100 mg/day), or placebo. The total study treatment duration was 10
weeks for children and 13 weeks for adolescents (<xref ref-type="supplementary-material" rid="SD1-ndt-12-1085">Figure S1A</xref>).</p><p>GXR was administered as tablets (1, 2, 3, and 4 mg) and ATX as capsules (10, 18,
25, 40, and 60 mg) in a double-dummy design. Titration of the two drugs has been
previously described.<xref rid="b19-ndt-12-1085" ref-type="bibr">19</xref>
Briefly, GXR dosing was initiated at 1 mg/day and increased by 1 mg increments
after a minimum of 1 week to a maximum dose of 4 mg/day in children and
4&#x02013;7 mg/day in adolescents (optimal GXR dose of 0.05&#x02013;0.12
mg/kg/day). ATX dosing was initiated at approximately 0.5 mg/kg/day in children
and adolescents weighing less than 70 kg at baseline, and increased after a
minimum of 1 week to the target of approximately 1.2 mg/kg/day. If well tolerated,
ATX dosing could be further increased to a maximum of 1.4 mg/kg/day after at least
1 week. ATX dosing in participants weighing 70 kg or more at baseline was
initiated at 40 mg/day, increased after at least a week to 80 mg/day, and after a
further week could be increased to 100 mg/day, if required; this was the total
permitted maximum daily dose. ATX was titrated as supported by the prescribing
information/summary of product characteristics European label.<xref rid="b16-ndt-12-1085" ref-type="bibr">16</xref></p><p>Response was defined as a &#x02265;30% reduction in ADHD-RS-IV total score from
baseline, and a CGI &#x02013; Improvement (CGI-I) rating of 1 (very much improved)
or 2 (much improved) in the absence of safety or tolerability issues.
Investigators could titrate to a higher dose if they believed that more beneficial
effects could be achieved.</p></sec><sec><title>RWS</title><p>The RWS was a multicenter, double-blind, placebo-controlled study. This study
started with an OL 7-week dose-optimization period during which participants
received GXR (1&#x02013;7 mg/day), followed by 6 weeks&#x02019; OL maintenance of
the optimized dose (NCT01081145; EUdraCT 2009-018161-12).<xref rid="b20-ndt-12-1085" ref-type="bibr">20</xref>,<xref rid="b21-ndt-12-1085" ref-type="bibr">21</xref> After the dose-optimization phase, participants were randomized to
continue GXR or to placebo for assessment of maintenance of efficacy, but data
from the randomized phase are not included in this analysis. The study was
conducted in 67 centers in Europe, the US, and Canada between May 2010 and June
2013 (<xref ref-type="supplementary-material" rid="SD1-ndt-12-1085">Figure
S1B</xref>).</p><p>GXR administration and titration during the OL phase of the RWS were as described
for the RCT. Response was defined as a &#x02265;30% reduction in ADHD-RS-IV total
score from baseline and a CGI-S rating of 1 (normal) or 2 (minimally ill) with
tolerable side effects.</p></sec></sec><sec><title>Prior treatment</title><p>For all participants who had previously received stimulant medication for ADHD,
details of the last stimulant treatment (ie, stimulant treatment that occurred prior
to the 3- to 35-day washout/screening period of study initiation) and reasons for
stopping were recorded at the baseline visit of both studies using a prespecified,
standardized questionnaire (Prior Stimulant Medication Questionnaire). Duration of
prior stimulant treatment was not recorded. The responses to each question were not
mutually exclusive. Reasons for stopping the last prior medication were summarized.
For participants who cited lack of efficacy as the reason for stopping, the reported
reasons were subsequently reviewed by two clinicians to ensure the appropriate
categorization of the response.</p></sec><sec sec-type="methods"><title>Analysis methodology</title><p>The analysis of response to GXR and ATX was conducted according to
participants&#x02019; prior stimulant-treatment status, as recorded in the Prior
Stimulant Medication Questionnaire. Those who had received prior stimulants were
grouped by the last stimulant received (&#x0201c;prior MPH&#x0201d; included any MPH
preparation; &#x0201c;prior non-MPH&#x0201d; included any other stimulant medication
for ADHD). The efficacy analysis was performed on the change in ADHD-RS-IV total
score from baseline. For the RCT, the change at visit 15/end point for each prior
treatment subgroup was compared for GXR or ATX versus placebo. For the OL phase of
the RWS, where participants only received GXR, the change at visit 13/OL end point
was summarized for prior treatment subgroups.</p><p>A priori, two levels of response were defined: a &#x02265;50% or a &#x02265;30%
reduction from baseline in the ADHD-RS-IV total score. For each responder definition,
the proportion of responders in each prior treatment subgroup was summarized for both
studies, and for the RCT only the difference in the proportion of responders between
treatment groups (GXR or ATX versus placebo) compared for each responder definition,
with 95% confidence intervals (CIs). Time to response (days) was also summarized for
each responder definition by prior treatment subgroup for both studies, and compared
between treatment groups for the RCT only.</p><p>The CGI-I and CGI-S ratings were collected at visit 15/end point for the RCT and
visit 13/OL endpoint for the RWS. For CGI-I, participants were classified as either
&#x0201c;improved&#x0201d; (scores 1 or 2) or &#x0201c;not improved&#x0201d; (score
of 3 or more combined into one category). For CGI-S, participants were classified as
either &#x0201c;normal/borderline ill&#x0201d; (scores 1 or 2) or &#x0201c;mildly ill
or greater&#x0201d; (score of 3 or more combined into one category). The percentages
of participants meeting response criteria were summarized by prior treatment subgroup
for both studies, and compared between treatment groups (GXR or ATX versus placebo)
for the RCT only.</p></sec><sec><title>Ad hoc analyses (RCT)</title><p>Two further levels of response, which combined ADHD-RS-IV scores and CGI-I,<xref rid="b22-ndt-12-1085" ref-type="bibr">22</xref> were defined in the RCT to explore
differences between GXR or ATX and placebo responses in the full RCT study
population: a &#x02265;50% or &#x02265;30% change from baseline in ADHD-RS-IV total
score combined with a CGI-I score of 1 or 2.</p></sec><sec><title>Statistical analyses</title><p>All participants who were randomized and received at least one dose of
investigational drug were included in the full-analysis set for each trial. Data from
the RCT and RWS were analyzed separately. <italic>P</italic>-values were not adjusted
for increased type I error, due to multiple end points and multiple comparisons, and
are presented as descriptive statistics. No head-to-head comparison between GXR and
ATX was made. Results with <italic>P</italic>&#x0003c;0.05 were regarded as nominally
significant.</p><sec><title>RCT</title><p>In the RCT, the efficacy analyses conducted on the change in ADHD-RS-IV score from
baseline to visit 15/end point between GXR or ATX and placebo used an analysis of
covariance model, which included terms for treatment group (effect of interest),
the corresponding baseline score (covariate), and blocking factors of age-group
(6&#x02013;12 or 13&#x02013;17 years) and country. Countries with low recruitment
in the RCT were pooled into three groups (Italy, Austria, France, Sweden, Ireland,
and the UK; Poland and Romania; the US and Canada); the other countries (Germany,
Spain, Ukraine) were left unpooled. The least squares (LS) means and standard
error of the mean for the treatment groups, difference in LS means between the
treatment groups with 95% CIs, ES with 95% CIs (calculated as the absolute
difference in LS means between active treatment and placebo, divided by the
root-mean-square error), and <italic>P</italic>-values for differences between
treatment groups were calculated.</p><p>The proportion of responders was compared between active treatment groups and
placebo using a Cochran&#x02013;Mantel&#x02013;Haenszel test stratified by
age-group and country. Summary statistics for time to response (in days) and
Kaplan&#x02013;Meier estimates of the 25th percentile, median, and 75th percentile
(and corresponding 95% CIs) were calculated for each treatment group. CGI-I and
CGI-S data were analyzed using a Cochran&#x02013;Mantel&#x02013;Haenszel test
stratified by age-group and country to examine treatment-group effects at visit
15/end point in the RCT. The last observation carried forward approach was used to
impute missing data for the efficacy analyses. Missing data were carried forward
for all visits except baseline.</p></sec><sec><title>RWS</title><p>Data from the RWS were tabulated and are presented only descriptively.</p></sec></sec></sec><sec sec-type="results"><title>Results</title><sec sec-type="subjects"><title>Participants</title><p>The overall participant disposition is shown in <xref ref-type="fig" rid="f1-ndt-12-1085">Figure 1</xref>. Of 337 participants randomized and treated
in the RCT, 163 (48.4%) reported prior stimulant medication use via the Prior
Stimulant Medication Questionnaire (placebo, n=56; GXR, n=53; ATX, n=54) (<xref ref-type="table" rid="t1-ndt-12-1085">Table 1</xref>). A total of 142 (42.1%)
participants reported that their last prior stimulant was a formulation of MPH
(placebo, n=48; GXR, n=46; ATX, n=48). One participant randomized to GXR who reported
prior MPH use did not provide any post-baseline efficacy data, and was therefore
excluded from the efficacy analysis. Owing to the small number of participants who
reported receiving a non-MPH stimulant (n=21, 6.2%), and the heterogeneity of prior
non-MPH treatments received, this subgroup was excluded from further reporting.
Analysis of the ADHD-RS-IV efficacy end point on the full data set including these
participants showed that their exclusion had no overall effect on the results (see
&#x0201c;Supplementary materials&#x0201d; and <xref ref-type="supplementary-material" rid="SD2-ndt-12-1085">Table S1</xref>). The remaining 174 (51.6%) participants
were classified as stimulant-na&#x000ef;ve (placebo, n=55; GXR, n=61; ATX, n=58). The
total number of participants reporting prior ATX use (n=40, 11.9%) was considered too
small for further investigation.</p><p>Of 503 participants treated in the OL phase of the RWS, 296 (58.8%) participants
reported prior stimulant-medication use (<xref ref-type="table" rid="t1-ndt-12-1085">Table 1</xref>). Only 72 (14.3%) reported that their last prior stimulant was a
non-MPH treatment; again, data from this subgroup were not reported, leaving 224
(44.5%) participants who reported that their last prior stimulant was an MPH
medication and 207 (41.2%) who were stimulant-na&#x000ef;ve.</p><p>Baseline demographics and disease characteristics for the RCT (n=337) and the RWS
(n=526, with n=503 included in the full-analysis set) are shown in <xref ref-type="table" rid="t2-ndt-12-1085">Table 2</xref>. Details of the full trial
populations are published in greater detail elsewhere.<xref rid="b19-ndt-12-1085" ref-type="bibr">19</xref>&#x02013;<xref rid="b21-ndt-12-1085" ref-type="bibr">21</xref> Mean (standard deviation [SD])
ages between groups/studies ranged from 10.1 (2.8) years to 11.5 (2.5) years, the
majority of participants in both studies were boys, and there tended to be more boys
in each of the prior MPH subgroups. The combined subtype of ADHD was most prevalent
in all subgroups.</p><p>Mean (SD) weight-adjusted dose of GXR at the end of the RCT was 0.09 (0.03) mg/kg/day
for both prior MPH and stimulant-na&#x000ef;ve subgroups. For ATX, the final
weight-adjusted doses were 1.0 (0.27) mg/kg/day and 1.0 (0.22) mg/kg/day for prior
MPH and stimulant-na&#x000ef;ve subgroups, respectively. At the end of the OL phase
in the RWS, the mean (SD) weight-adjusted dose of GXR was 0.09 (0.03) mg/kg/day for
the prior MPH subgroup and 0.08 (0.03) mg/kg/day for the stimulant-na&#x000ef;ve
subgroup.</p></sec><sec><title>Reasons for stopping MPH treatment</title><p>Reasons provided on the Prior Stimulant Medication Questionnaire for stopping MPH
treatment are shown in <xref ref-type="table" rid="t3-ndt-12-1085">Table 3</xref>. In
the RCT, reasons included lack of effectiveness (56%), side effects (37%), and
wanting to switch medication (29%); in the RWS, reasons included lack of
effectiveness (65%), side effects (55%), and wanting to stop taking stimulant
medication (11%).</p></sec><sec><title>Efficacy analyses by prior treatment subgroup</title><sec><title>Change from baseline in ADHD-RS-IV</title><p>Mean changes from baseline to end point in ADHD-RS-IV score for each study are
shown in <xref ref-type="fig" rid="f2-ndt-12-1085">Figure 2</xref>. In the RCT,
nominally significant placebo-adjusted differences in LS mean change from baseline
to end point on the ADHD-RS-IV were observed in GXR-treated participants, in both
subgroups (prior MPH, &#x02212;9.8 [95% CI &#x02212;14.6 to
&#x02212;5.1], <italic>P</italic>&#x0003c;0.001, ES 0.85;
stimulant-na&#x000ef;ve: &#x02212;7.6 [95% CI &#x02212;11.8 to
&#x02212;3.3], <italic>P</italic>&#x0003c;0.001, ES 0.65). In ATX-treated
participants, a nominally significant placebo-adjusted difference in LS mean
change from baseline to end point in ADHD-RS-IV was seen in the
stimulant-na&#x000ef;ve subgroup but not the prior MPH subgroup (prior MPH,
&#x02212;1.8 [95% CI &#x02212;6.5&#x02013;2.9],
<italic>P</italic>&#x0003e;0.05, ES 0.15; stimulant-na&#x000ef;ve, &#x02212;5.0
[95% CI &#x02212;9.4 to &#x02212;0.7], <italic>P</italic>=0.022,
ES 0.43).</p><p>In the OL phase of the RWS, changes from baseline in ADHD-RS-IV total score for
GXR-treated participants were similar in the prior MPH and stimulant-na&#x000ef;ve
subgroups (<xref ref-type="fig" rid="f2-ndt-12-1085">Figure 2</xref>).</p><p>As prior MPH treatment may influence the placebo effect indirectly due to
patients&#x02019; prior experience and expectations of the effects of MPH
treatment, or by any other neurobiological or psychological pathway, we also
compared placebo response in the subgroups. Placebo response in the RCT
(ADHD-RS-IV total score change from baseline [95% CI]) was lower
for prior MPH patients (&#x02212;13.5 [&#x02212;17.4 to
&#x02212;9.5]) than stimulant-na&#x000ef;ve patients (&#x02212;15.9
[&#x02212;19.0 to &#x02212;12.8]), although the overlapping CIs
indicate that the difference was not significant.</p><p>The efficacy analysis by reason for stopping prior treatment is reported in the
&#x0201c;Supplementary materials&#x0201d; section (<xref ref-type="supplementary-material" rid="SD3-ndt-12-1085">Table S2</xref>).</p></sec><sec sec-type="methods"><title>Responder analysis</title><p>Responder analyses from the RCT are shown in <xref ref-type="table" rid="t4-ndt-12-1085">Table 4</xref>. The difference from placebo in the
proportion of participants achieving a &#x02265;50% reduction from baseline in
ADHD-RS-IV total score was nominally significant in GXR-treated participants in
both the prior MPH-treated and stimulant-na&#x000ef;ve subgroups (difference from
placebo [95% CI]: prior MPH, 24.2%
[4.7&#x02013;43.6], <italic>P</italic>=0.011;
stimulant-na&#x000ef;ve, 25.5% [7.8&#x02013;43.1],
<italic>P</italic>=0.003). In ATX-treated participants, nominally significant
differences versus placebo were seen only in the stimulant-na&#x000ef;ve subgroup
(difference from placebo [95% CI]: prior MPH, 2.1%
[&#x02212;16.3 to 20.4], <italic>P</italic>=0.911;
stimulant-na&#x000ef;ve, 22.4% [4.5&#x02013;40.3],
<italic>P</italic>=0.010).</p><p>A similar pattern of results was noted in the proportion of participants achieving
a &#x02265;30% reduction from baseline in ADHD-RS-IV total score. A nominally
significantly higher proportion of GXR-treated participants achieved this response
regardless of prior treatment status (difference from placebo [95%
CI]: prior MPH, 27.8% [9.1&#x02013;46.4],
<italic>P</italic>=0.008; stimulant-na&#x000ef;ve, 25.2%
[9.1&#x02013;41.2], <italic>P</italic>&#x0003c;0.001). For
ATX-treated participants, again, only the stimulant-na&#x000ef;ve subgroup
achieved a &#x02265;30% response (19.4% [2.5&#x02013;36.3],
<italic>P</italic>=0.008; prior MPH, 8.3% [&#x02212;11.5 to
28.2], <italic>P</italic>=0.511).</p><p>In the OL phase of the RWS, there were 9.1% more participants achieving a
&#x02265;50% reduction from baseline in ADHD-RS-IV total score with GXR in the
stimulant-na&#x000ef;ve subgroup compared with the prior MPH subgroup (73.8%
[67.8%&#x02013;79.8%], 64.7%
[58.4%&#x02013;71.0%]); a &#x02265;30% reduction from baseline
ADHD-RS-IV total score was achieved by 6.5% more participants in the
stimulant-na&#x000ef;ve subgroup than the prior MPH subgroup (87.9%
[83.4%&#x02013;92.3%], 81.4%
[76.3%&#x02013;86.6%]).</p><p>The time-to-response analysis is reported in the &#x0201c;Supplementary
materials&#x0201d; section (<xref ref-type="supplementary-material" rid="SD4-ndt-12-1085">Table S3</xref>).</p></sec><sec><title>CGI-I and CGI-S</title><p>In the RCT, among stimulant-na&#x000ef;ve participants, a nominally significantly
higher proportion of GXR- and ATX-treated participants had improved CGI-I (score
of 1 or 2) at end point compared with placebo (<xref ref-type="fig" rid="f3-ndt-12-1085">Figure 3</xref>; difference [95% CI]: GXR,
27.9% [10.6%&#x02013;45.2%], <italic>P</italic>&#x0003c;0.001;
ATX, 20.1% [2.1%&#x02013;38.0%], <italic>P</italic>=0.005).
However, no nominally significant difference versus placebo was seen in the prior
MPH subgroup (GXR, 16.1% [&#x02212;4.0% to 36.2%],
<italic>P</italic>=0.090; ATX, 0 [&#x02212;19.7% to 19.7%],
<italic>P</italic>=0.857). In the OL RWS, 10.8% more participants treated with
GXR had improved CGI-I scores at end point in the stimulant-na&#x000ef;ve subgroup
compared with the prior MPH subgroup.</p><p>Also in the RCT, at end point, there were no significant differences in proportion
of participants categorized as normal/borderline ill (CGI-S score of 1 or 2) from
placebo among those treated with GXR or ATX in the prior MPH (difference
[95% CI]: GXR, 16.8% [&#x02212;1.0% to 34.6%],
<italic>P</italic>=0.070; ATX, &#x02212;4.2% [&#x02212;19.1% to
10.7%], <italic>P</italic>=0.516) and stimulant-na&#x000ef;ve subgroups
(difference [95% CI]: GXR, 12.7% [&#x02212;4.4% to
29.8%], <italic>P</italic>=0.073; ATX, 7.2% [&#x02212;9.8% to
24.2%], <italic>P</italic>=0.242) (<xref ref-type="supplementary-material" rid="SD5-ndt-12-1085">Table S4</xref>).</p></sec></sec><sec><title>Ad hoc analyses (RCT only)</title><p>Responder analyses showed nominally significant differences versus placebo in GXR-
and ATX-treated participants at both combined response levels (<xref ref-type="supplementary-material" rid="SD6-ndt-12-1085">Table S5</xref>). For the
&#x02265;30% combined response level, differences (95% CI) in the percentage of
responders from placebo were 21.9% (9.2%&#x02013;34.7%,
<italic>P</italic>&#x0003c;0.001) for GXR-treated participants and 13.0%
(0&#x02013;26.0%, <italic>P</italic>=0.017) for ATX-treated participants. For the
&#x02265;50% combined response level, differences from placebo (95% CI) were 23.8%
(11.3%&#x02013;36.4%, <italic>P</italic>&#x0003c;0.001) for GXR-treated participants
and 12.2% (&#x02212;0.2% to 24.7%, <italic>P</italic>=0.018) for ATX-treated
participants.</p></sec><sec><title>Safety</title><p>For the full study population in the RCT, 77.2% of those receiving GXR, 67.9% of
those receiving ATX, and 65.8% of those in the placebo group reported
treatment-emergent adverse events (TEAEs).<xref rid="b19-ndt-12-1085" ref-type="bibr">19</xref> Serious TEAEs considered related to treatment were reported in one
participant in the placebo group and one in the GXR group, with the latter leading to
discontinuation. Overall in the RCT, a low proportion of participants discontinued
due to TEAEs (0.9% placebo, 7.9% GXR, 4.5% ATX).<xref rid="b19-ndt-12-1085" ref-type="bibr">19</xref> In the OL phase of the RWS, 85.2% of participants
reported TEAEs.<xref rid="b20-ndt-12-1085" ref-type="bibr">20</xref>,<xref rid="b21-ndt-12-1085" ref-type="bibr">21</xref> There were five serious adverse
events (AEs) considered related to treatment, three of which led to discontinuation.
Overall, in the OL phase of the RWS, 8.0% of participants discontinued due to
TEAEs.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>This study examined whether prior treatment with MPH affects response to GXR using
prespecified analyses of data from two international Phase III studies. GXR-treated
participants demonstrated nominally statistically significant improvements in all
ADHD-symptom measures (ADHD-RS-IV scores, responder analyses, and time to response) in
both stimulant-na&#x000ef;ve and prior MPH-treated participants compared with placebo.
ADHD-symptom improvements in ATX-treated participants separated from placebo, but not
when ATX was given after prior MPH treatment. The clinical relevance of the analysis of
GXR efficacy in individuals with ADHD who had previously received MPH is highlighted by
the approval of GXR in Europe for children and adolescents for whom stimulants are not
suitable, not tolerated, or have been shown to be ineffective.<xref rid="b14-ndt-12-1085" ref-type="bibr">14</xref></p><p>The finding of a relatively lower response to ATX in participants previously treated
with MPH compared with stimulant-na&#x000ef;ve participants is consistent with previous
findings from a randomized, double-blind, placebo-controlled study comparing ATX, MPH,
and placebo over a 6-week period.<xref rid="b17-ndt-12-1085" ref-type="bibr">17</xref>
In the acute comparison phase, for participants previously treated with a stimulant, the
mean (SD) change from baseline in ADHD-RS-IV scores was significantly different between
the MPH-treated group (&#x02212;15.1 [13.1]) and the ATX-treated group
(&#x02212;12.4 [12.2], <italic>P</italic>=0.04), and the proportion of
responders (40% decrease in ADHD-RS-IV score from baseline to end point) in the ATX
group (37%) was not significantly different from placebo (23%). A meta-regression
analysis of 25 double-blind RCTs of ATX also showed a significant relationship between
treatment na&#x000ef;vet&#x000e9; and degree of response to ATX, with the greater
response in those na&#x000ef;ve to ADHD treatment<xref rid="b18-ndt-12-1085" ref-type="bibr">18</xref> supporting the suggestion of a difference in response
to ATX depending on prior treatment.</p><p>Shared mechanisms between stimulants and ATX may explain how a previous inadequate
response to MPH may predict a poorer outcome to subsequent treatment with ATX than it
does for GXR. Both MPH and ATX block uptake of extracellular catecholamines. Although
ATX is selective for the noradrenaline transporter, because dopamine reuptake in the
prefrontal cortex is primarily managed by the noradrenaline transporter, ATX, such as
MPH, increases extracellular concentrations of both noradrenaline and dopamine in this
region.<xref rid="b15-ndt-12-1085" ref-type="bibr">15</xref>,<xref rid="b23-ndt-12-1085" ref-type="bibr">23</xref>,<xref rid="b24-ndt-12-1085" ref-type="bibr">24</xref>
Further, prior treatment with stimulants may change susceptibility to subsequent drug
treatment at either a pharmacological or physiological psychological level; striatal
dopamine-transporter density has been found to be increased in individuals previously
treated with stimulants, possibly due to adaptation of the brain to continuous
dopamine-transporter blockade.<xref rid="b25-ndt-12-1085" ref-type="bibr">25</xref>,<xref rid="b26-ndt-12-1085" ref-type="bibr">26</xref> In contrast, GXR is
a direct and selective agonist for &#x003b1;2A-adrenergic receptors and does not
directly affect transporter function, hence there is limited overlap with the mechanism
of action of stimulants. Reports that genetic variants in the <italic>CES1</italic> gene
encoding the major MPH-metabolizing enzyme and the dopamine-transporter gene
<italic>SLC6A3</italic> affect the response or side-effect profile of MPH<xref rid="b27-ndt-12-1085" ref-type="bibr">27</xref>,<xref rid="b28-ndt-12-1085" ref-type="bibr">28</xref> suggest that genetic biomarkers of response to ADHD
medications are an important avenue for future research. However, this discussion
notwithstanding, it should be noted that not all participants previously treated with
MPH in this analysis necessarily had an inadequate response, as other reasons for
stopping prior MPH treatment were also given (although inadequate response was a primary
reason for stopping MPH).</p><p>The RWS was analyzed to provide GXR data from a larger data set regarding response to
GXR in participants who were previously treated with MPH or stimulant-na&#x000ef;ve, and
generally confirmed the findings in direction and magnitude of response seen in the RCT.
Similarly, the ad hoc analyses of combined ADHD-RS-IV and CGI-I responses at two
thresholds confirmed that both GXR and ATX treatments gave robust responses in the RCT
compared with placebo.</p><p>Responder analyses are widely accepted in the field, although there is currently no
consensus regarding the most appropriate response criteria; previous analyses of ADHD
treatments have employed specified percentage reductions from baseline in ADHD-RS-IV
total score, a CGI-I score of 1 or 2, or a combination of the two.<xref rid="b3-ndt-12-1085" ref-type="bibr">3</xref>,<xref rid="b29-ndt-12-1085" ref-type="bibr">29</xref>&#x02013;<xref rid="b31-ndt-12-1085" ref-type="bibr">31</xref> The use of
different levels of response in the present study provides information at different
levels of stringency. Response rates decreased with increasingly stringent definitions,
as would be expected. We also found that generally the same trend or outcome was found,
regardless of the definition used.</p><p>Both GXR and ATX significantly improved CGI-I scores at RCT end point compared with
placebo in the stimulant-na&#x000ef;ve subgroup; however, no statistical improvement
relative to placebo was seen in the prior MPH subgroup for either GXR- or ATX-treated
participants. For GXR, this result approached but did not reach nominal significance
(<italic>P</italic>=0.09), which is in contrast to the ADHD-RS-IV results. There was
no nominally significant difference between GXR or ATX and placebo in either the
stimulant-na&#x000ef;ve or prior MPH subgroups in the proportion of participants at end
point with CGI-S scores indicating &#x0201c;normal/borderline&#x0201d; severity of
symptoms, although for GXR this result approached nominal significance in the
stimulant-na&#x000ef;ve (<italic>P</italic>=0.073) and prior MPH
(<italic>P</italic>=0.07) subgroups. The OL phase of the RWS showed a much greater
degree of improvement in CGI-S to that seen in the RCT, possibly as a result of the OL
nature of the study. It is not entirely clear why the CGI measure was less sensitive
than the ADHD-RS-IV to detect medication effects in this study, although the ordinal
(CGI-I) versus continuous (ADHD-RS) characteristics of these assessments may have been a
factor. Given this result, and the indirect nature of the comparison between GXR and ATX
in the current study design, more systematic research is required.</p></sec><sec><title>Limitations</title><p>Our findings should be interpreted in the context of several limitations. With regard to
study design, the current analyses were not originally powered for a head-to-head
comparison between the active treatments (the study was designed to detect differences
between active treatment arms and placebo based on the ADHD-RS-IV); however, these
analyses were prespecified in the original study protocols in a separate statistical
analysis plan prior to database lock. The categorization of participants as prior MPH or
stimulant-na&#x000ef;ve was based on responses to the Prior Stimulant Medication
Questionnaire. Once analyses were complete, a small subset of non-MPH-treated
participants in the prior stimulant group were excluded, which slightly reduced the
sample size. However, a sensitivity analysis of the full prior stimulant group showed
that this exclusion did not affect the overall results. Children and adolescents
previously treated with nonstimulants were likewise excluded from this study, because
the number of such participants in the present studies were too small to permit such
analyses. There are also a number of considerations related to the recording of previous
treatment. In the Prior Stimulant Medication Questionnaire, the reasons for stopping
prior medication were not mutually exclusive, as participants could give more than one
reason. Participants who claimed efficacy failure had no clinical measures recorded to
indicate the degree of inadequate response to prior treatment, nor the number of trials
or duration of prior therapies. We also had no information on whether the dosing or
titration of prior MPH treatment was adequate, and thus no stratification for potential
prior dosage differences was possible at randomization.</p><p>It is also acknowledged that although both GXR and ATX were dose-optimized in the RCT
based on the respective prescribing information/summary of product characteristics for
each product, the clinically recommended dose for ATX (1.2 mg/kg) is somewhat higher
than the mean end-of-treatment dose of 1.0 mg/kg in the present study, possibly as the
result of AEs or other factors that may have limited the ability to titrate ATX to the
optimal dose rapidly. However, the 6-week maintenance-treatment period in the RCT did
give sufficient time for participants to achieve their fullest potential response at the
optimized dose for both medications.<xref rid="b19-ndt-12-1085" ref-type="bibr">19</xref> Finally, it should be noted that this study found a numerically but
nominally statistically nonsignificant larger placebo response in the
stimulant-na&#x000ef;ve group than in the prior MPH group, supporting other research
suggesting that previous MPH exposure may influence the placebo response.<xref rid="b17-ndt-12-1085" ref-type="bibr">17</xref>,<xref rid="b29-ndt-12-1085" ref-type="bibr">29</xref> Future research, therefore, should specifically
address the question of whether prior exposure to MPH changes the outcome on subsequent
pharmacological exposure.</p></sec><sec><title>Conclusion</title><p>Although there are no published studies that address the sequential efficacy of ADHD
medication as their primary objective, such studies as the present one can be
informative. Subgroup analyses in this study highlight the importance of considering the
medication history of children and adolescents with ADHD to help guide clinical
intervention for individual patients, and ultimately algorithm development. As has been
previously reported, secondary analyses of the RCT indirectly favored GXR versus ATX in
a prespecified comparison of the change from baseline in ADHD-RS-IV total score at end
point.<xref rid="b19-ndt-12-1085" ref-type="bibr">19</xref> Results from the
prespecified analyses reported here suggest that the efficacy observed in participants
treated with GXR but not ATX may be somewhat explained by the prior MPH-treated cohort.
These are the first studies to examine differences in response to different nonstimulant
medications as a function of prior stimulant exposure. However, even though
prespecified, the present results are exploratory, and further research is needed to
confirm these findings.</p></sec><sec sec-type="supplementary-material"><title>Supplementary materials</title><sec sec-type="methods"><title>Efficacy analysis including prior non-MPH subgroup</title><p>A sensitivity analysis of the change in baseline Attention-Deficit/Hyperactivity
Disorder Rating Scale version IV (ADHD-RS-IV) total score, including the participants
who had reported that their last prior stimulant was a non-methylphenidate (MPH)
treatment, is shown in <xref ref-type="supplementary-material" rid="SD2-ndt-12-1085">Table S1</xref> for the randomized controlled trial (RCT). As for the comparison
between the prior MPH and stimulant-na&#x000ef;ve subgroups, nominally significant
placebo-adjusted differences in least squares (LS) mean change from baseline to end
point on the ADHD-RS-IV were observed in guanfacine extended release (GXR)-treated
participants, in both subgroups (any prior stimulant, &#x02212;10.0 [95%
confidence interval [CI] &#x02212;14.4 to &#x02212;5.6],
<italic>P</italic>&#x0003c;0.001, effect size {ES} 0.86; stimulant-na&#x000ef;ve,
&#x02212;7.6 [95% CI &#x02212;11.8 to &#x02212;3.3],
<italic>P</italic>&#x0003c;0.001, ES 0.66). In atomoxetine (ATX)-treated
participants, a nominally significant placebo-adjusted difference in LS mean change
from baseline to end point in ADHD-RS-IV was seen in the stimulant-na&#x000ef;ve
subgroup, but not the prior stimulant subgroup (any prior stimulant, &#x02212;2.0
[95% CI &#x02212;6.4 to 2.3], <italic>P</italic>=0.365, ES 0.17;
stimulant-na&#x000ef;ve, &#x02212;5.1 [95% CI &#x02212;9.3 to
&#x02212;0.8], <italic>P</italic>=0.021, ES 0.44).</p></sec><sec sec-type="methods"><title>Efficacy analysis by reason for stopping prior MPH treatment</title><p>The efficacy analysis by reason for stopping prior treatment is shown in <xref ref-type="supplementary-material" rid="SD3-ndt-12-1085">Table S2</xref>. The
placebo-adjusted differences in LS mean change from baseline to end point in
ADHD-RS-IV total score for those participants who had stopped prior MPH for efficacy
reasons (n=88) were nominally significantly different in GXR- and placebo-treated
participants (&#x02212;10.8 [95% CI &#x02212;18.5 to &#x02212;3.2],
<italic>P</italic>=0.006, ES 0.78), but not in ATX- and placebo-treated
participants (&#x02212;5.3 [95% CI &#x02212;12.7 to 2.2],
<italic>P</italic>=0.161, ES 0.38). The same pattern and magnitude of response was
seen for those participants who had stated safety or tolerability reasons for
stopping prior MPH, or for other reasons.</p></sec><sec><title>Time to response</title><p>Time to response for the &#x02265;50% reduction from baseline in ADHD-RS-IV total
score was nominally significantly different from placebo in GXR-treated participants
in both subgroups (median [95% CI] time: prior MPH, 34
[22&#x02013;48] days, <italic>P</italic>=0.013;
stimulant-na&#x000ef;ve, 34 [28&#x02013;67] days,
<italic>P</italic>=0.001). However, it was not nominally significant in either
subgroup among ATX-treated participants (median [95% CI] time: prior
MPH, 49 [37 to incalculable] days, <italic>P</italic>=0.629;
stimulant-na&#x000ef;ve, 56 [35&#x02013;70] days,
<italic>P</italic>=0.061; <xref ref-type="supplementary-material" rid="SD4-ndt-12-1085">Table S3</xref>). The time to response with GXR, as defined
by a &#x02265;30% reduction from baseline in ADHD-RS-IV total score response,
followed the same significance pattern (median [95% CI] time: prior
MPH, 21 [14&#x02013;27] days, <italic>P</italic>=0.024;
stimulant-na&#x000ef;ve, 25 [20&#x02013;33] days,
<italic>P</italic>=0.006). However, ATX-treated participants differed slightly, as a
nominally significantly shorter time to response than placebo was achieved for the
stimulant-na&#x000ef;ve subgroup, but not the prior MPH subgroup (median [95%
CI] time: prior MPH, 28 [21&#x02013;33] days,
<italic>P</italic>=0.216; stimulant-na&#x000ef;ve, 28
[21&#x02013;35] days, <italic>P</italic>=0.042). The time to response
was similar in GXR-treated participants in both the prior MPH and
stimulant-na&#x000ef;ve subgroups in the open-label phase of the
randomized-withdrawal study for both the &#x02265;50% threshold (median [95%
CI] time: prior MPH, 36 [35&#x02013;42] days;
stimulant-na&#x000ef;ve, 29 [27&#x02013;35] days) and the
&#x02265;30% threshold (median [95% CI] time: prior MPH, 23
[21&#x02013;27] days; stimulant-na&#x000ef;ve, 20
[15&#x02013;21] days).</p><supplementary-material content-type="local-data" id="SD1-ndt-12-1085"><label>Figure S1</label><caption><p>Study designs for (<bold>A</bold>) randomized controlled trial and
(<bold>B</bold>) randomized-withdrawal study.</p><p><bold>Note:</bold> Only data from the open-label phase were used in this
analysis.</p><p><bold>Abbreviation:</bold> GXR, guanfacine extended release.</p></caption><media mimetype="image" mime-subtype="tif" xlink:href="ndt-12-1085s1.tif" xlink:type="simple" id="d36e738" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD2-ndt-12-1085"><table-wrap id="ts1-ndt-12-1085" position="float"><label>Table S1</label><caption><p>ANCOVA analysis of change from baseline to end point in ADHD-RS-IV total
score by prior stimulant use in the RCT (LOCF; full-analysis set)</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Test vs comparator</th><th valign="top" align="left" rowspan="1" colspan="1">LS mean (SE)<xref ref-type="table-fn" rid="tfn10-ndt-12-1085">*</xref> test</th><th valign="top" align="left" rowspan="1" colspan="1">LS mean (SE)<xref ref-type="table-fn" rid="tfn10-ndt-12-1085">*</xref> comparator</th><th valign="top" align="left" rowspan="1" colspan="1">Difference in LS mean treatment &#x02013;
comparator (95% CI)</th><th valign="top" align="left" rowspan="1" colspan="1">Effect size (95% CI)</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td colspan="6" valign="top" align="left" rowspan="1"><bold>Any prior stimulant<xref ref-type="table-fn" rid="tfn11-ndt-12-1085">&#x02020;</xref></bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GXR<xref ref-type="table-fn" rid="tfn12-ndt-12-1085">a</xref> vs placebo<xref ref-type="table-fn" rid="tfn13-ndt-12-1085">b</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;23.283 (1.6703)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;13.295 (1.6031)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;9.988 (&#x02212;14.369 to
&#x02212;5.608)</td><td valign="top" align="left" rowspan="1" colspan="1">0.86 (0.47 to 1.26)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ATX<xref ref-type="table-fn" rid="tfn14-ndt-12-1085">c</xref> vs placebo<xref ref-type="table-fn" rid="tfn13-ndt-12-1085">b</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;15.297 (1.6517)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;13.295 (1.6031)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;2.002 (&#x02212;6.347 to
2.344)</td><td valign="top" align="left" rowspan="1" colspan="1">0.17 (&#x02212;0.20 to 0.55)</td><td valign="top" align="left" rowspan="1" colspan="1">0.365</td></tr><tr><td colspan="6" valign="top" align="left" rowspan="1"><bold>Stimulant-na&#x000ef;ve</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GXR<xref ref-type="table-fn" rid="tfn15-ndt-12-1085">d</xref> vs placebo<xref ref-type="table-fn" rid="tfn16-ndt-12-1085">e</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;24.400 (1.5514)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;16.835 (1.6211)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;7.564 (&#x02212;11.802 to
&#x02212;3.327)</td><td valign="top" align="left" rowspan="1" colspan="1">0.66 (0.28 to 1.03)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ATX<xref ref-type="table-fn" rid="tfn17-ndt-12-1085">f</xref> vs placebo<xref ref-type="table-fn" rid="tfn16-ndt-12-1085">e</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;21.887 (1.5784)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;16.835 (1.6211)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;5.052 (&#x02212;9.344 to
&#x02212;0.759)</td><td valign="top" align="left" rowspan="1" colspan="1">0.44 (0.06 to 0.81)</td><td valign="top" align="left" rowspan="1" colspan="1">0.021</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold></p></fn><fn id="tfn10-ndt-12-1085"><label>*</label><p>A negative difference in LS mean (active treatment &#x02013; placebo)
indicates a positive effect of the active treatment over placebo;</p></fn><fn id="tfn11-ndt-12-1085"><label>&#x02020;</label><p>includes both prior MPH and prior non-MPH subgroups. Number of
observations per group at visit 15:</p></fn><fn id="tfn12-ndt-12-1085"><label>a</label><p>52,</p></fn><fn id="tfn13-ndt-12-1085"><label>b</label><p>56,</p></fn><fn id="tfn14-ndt-12-1085"><label>c</label><p>54,</p></fn><fn id="tfn15-ndt-12-1085"><label>d</label><p>60,</p></fn><fn id="tfn16-ndt-12-1085"><label>e</label><p>55, and</p></fn><fn id="tfn17-ndt-12-1085"><label>F</label><p>58.</p></fn><fn id="tfn18-ndt-12-1085"><p><bold>Abbreviations:</bold> ADHD-RS-IV, Attention-Deficit/Hyperactivity
Disorder Rating Scale version IV; ANCOVA, analysis of covariance; ATX,
atomoxetine; CI, confidence interval; GXR, guanfacine extended release;
LOCF, last observation carried forward; LS, least squares; MPH,
methylphenidate; SE, standard error; RCT, randomized controlled
trial.</p></fn></table-wrap-foot></table-wrap></supplementary-material><supplementary-material content-type="local-data" id="SD3-ndt-12-1085"><table-wrap id="ts2-ndt-12-1085" position="float"><label>Table S2</label><caption><p>ANCOVA analysis of change from baseline to end point in ADHD-RS-IV total
score by reason for stopping prior MPH treatment (LOCF; full-analysis
set)</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Test vs comparator</th><th valign="top" align="left" rowspan="1" colspan="1">LS mean (SE)<xref ref-type="table-fn" rid="tfn19-ndt-12-1085">*</xref> test</th><th valign="top" align="left" rowspan="1" colspan="1">LS mean (SE)<xref ref-type="table-fn" rid="tfn19-ndt-12-1085">*</xref> comparator</th><th valign="top" align="left" rowspan="1" colspan="1">Difference in LS mean treatment &#x02013;
comparator (95% CI)</th><th valign="top" align="left" rowspan="1" colspan="1">Effect size (95% CI)</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td colspan="6" valign="top" align="left" rowspan="1"><bold>Combined efficacy
failure</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GXR<xref ref-type="table-fn" rid="tfn20-ndt-12-1085">a</xref> vs placebo<xref ref-type="table-fn" rid="tfn21-ndt-12-1085">b</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;22.929 (3.9409)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;12.113 (3.4445)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;10.817 (&#x02212;18.480 to
&#x02212;3.154)</td><td valign="top" align="left" rowspan="1" colspan="1">0.78 (0.22 to 1.35)</td><td valign="top" align="left" rowspan="1" colspan="1">0.006</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ATX<xref ref-type="table-fn" rid="tfn22-ndt-12-1085">c</xref> vs placebo<xref ref-type="table-fn" rid="tfn21-ndt-12-1085">b</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;17.405 (3.7057)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;12.113 (3.4445)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;5.292 (&#x02212;12.735 to
2.150)</td><td valign="top" align="left" rowspan="1" colspan="1">0.38 (&#x02212;0.15 to 0.92)</td><td valign="top" align="left" rowspan="1" colspan="1">0.161</td></tr><tr><td colspan="6" valign="top" align="left" rowspan="1"><bold>Safety/tolerability</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GXR<xref ref-type="table-fn" rid="tfn23-ndt-12-1085">d</xref> vs placebo<xref ref-type="table-fn" rid="tfn24-ndt-12-1085">e</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;23.770 (4.1920)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;12.818 (3.6314)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;10.952 (&#x02212;21.115 to
&#x02212;0.789)</td><td valign="top" align="left" rowspan="1" colspan="1">0.73 (0.05 to 1.42)</td><td valign="top" align="left" rowspan="1" colspan="1">0.035</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ATX<xref ref-type="table-fn" rid="tfn23-ndt-12-1085">d</xref> vs placebo<xref ref-type="table-fn" rid="tfn24-ndt-12-1085">e</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;18.242 (4.1288)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;12.818 (3.6314)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;5.425 (&#x02212;15.720 to
4.871)</td><td valign="top" align="left" rowspan="1" colspan="1">0.36 (&#x02212;0.31 to 1.03)</td><td valign="top" align="left" rowspan="1" colspan="1">0.295</td></tr><tr><td colspan="6" valign="top" align="left" rowspan="1"><bold>Other reasons (excluding
inability to pay for medication)</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GXR<xref ref-type="table-fn" rid="tfn24-ndt-12-1085">e</xref> vs placebo<xref ref-type="table-fn" rid="tfn25-ndt-12-1085">f</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;38.148 (4.5166)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;22.345 (4.0536)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;15.803 (&#x02212;24.870 to
&#x02212;6.735)</td><td valign="top" align="left" rowspan="1" colspan="1">1.12 (0.44 to 1.80)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ATX<xref ref-type="table-fn" rid="tfn26-ndt-12-1085">g</xref> vs placebo<xref ref-type="table-fn" rid="tfn25-ndt-12-1085">f</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;23.179 (4.3409)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;22.345 (4.0536)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.834 (&#x02212;10.158 to
8.491)</td><td valign="top" align="left" rowspan="1" colspan="1">0.06 (&#x02212;0.56 to 0.68)</td><td valign="top" align="left" rowspan="1" colspan="1">0.859</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold></p></fn><fn id="tfn19-ndt-12-1085"><label>*</label><p>A negative difference in LS mean (active treatment &#x02013; placebo)
indicates a positive effect of the active treatment over placebo. Number
of observations per group at visit 15:</p></fn><fn id="tfn20-ndt-12-1085"><label>a</label><p>24,</p></fn><fn id="tfn21-ndt-12-1085"><label>b</label><p>28,</p></fn><fn id="tfn22-ndt-12-1085"><label>c</label><p>27,</p></fn><fn id="tfn23-ndt-12-1085"><label>d</label><p>17,</p></fn><fn id="tfn24-ndt-12-1085"><label>e</label><p>18,</p></fn><fn id="tfn25-ndt-12-1085"><label>F</label><p>21, and</p></fn><fn id="tfn26-ndt-12-1085"><label>g</label><p>19. Reasons not mutually exclusive.</p></fn><fn id="tfn27-ndt-12-1085"><p><bold>Abbreviations:</bold> ADHD-RS-IV, Attention-Deficit/Hyperactivity
Disorder Rating Scale version IV; ANCOVA, analysis of covariance; ATX,
atomoxetine; CI, confidence interval; GXR, guanfacine extended release;
LOCF, last observation carried forward; LS, least squares; MPH,
methylphenidate; SE, standard error.</p></fn></table-wrap-foot></table-wrap></supplementary-material><supplementary-material content-type="local-data" id="SD4-ndt-12-1085"><table-wrap id="ts3-ndt-12-1085" position="float"><label>Table S3</label><caption><p>Time to response by treatment for prior MPH or stimulant-na&#x000ef;ve
subgroups (LOCF, full-analysis set)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" valign="top" align="left" colspan="1">Definition of response</th><th rowspan="3" valign="top" align="left" colspan="1">Time to response</th><th colspan="6" valign="top" align="left" rowspan="1">RCT <hr/></th><th colspan="2" valign="top" align="left" rowspan="1">RWS <hr/></th></tr><tr><th colspan="2" valign="top" align="left" rowspan="1">Placebo (n=111) <hr/></th><th colspan="2" valign="top" align="left" rowspan="1">GXR (n=114) <hr/></th><th colspan="2" valign="top" align="left" rowspan="1">ATX (n=112) <hr/></th><th colspan="2" valign="top" align="left" rowspan="1">GXR (n=503) <hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Prior MPH</th><th valign="top" align="left" rowspan="1" colspan="1">Stimulant-na&#x000ef;ve</th><th valign="top" align="left" rowspan="1" colspan="1">Prior MPH</th><th valign="top" align="left" rowspan="1" colspan="1">Stimulant-na&#x000ef;ve</th><th valign="top" align="left" rowspan="1" colspan="1">Prior MPH</th><th valign="top" align="left" rowspan="1" colspan="1">Stimulant-na&#x000ef;ve</th><th valign="top" align="left" rowspan="1" colspan="1">Prior MPH</th><th valign="top" align="left" rowspan="1" colspan="1">Stimulant-na&#x000ef;ve</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02265;50% reduction from baseline in
ADHD-RS-IV</td><td valign="top" align="left" rowspan="1" colspan="1">Number of participants</td><td valign="top" align="left" rowspan="1" colspan="1">23</td><td valign="top" align="left" rowspan="1" colspan="1">25</td><td valign="top" align="left" rowspan="1" colspan="1">31</td><td valign="top" align="left" rowspan="1" colspan="1">41</td><td valign="top" align="left" rowspan="1" colspan="1">24</td><td valign="top" align="left" rowspan="1" colspan="1">36</td><td valign="top" align="left" rowspan="1" colspan="1">169</td><td valign="top" align="left" rowspan="1" colspan="1">174</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">total score</td><td valign="top" align="left" rowspan="1" colspan="1">Median (95% CI), days</td><td valign="top" align="left" rowspan="1" colspan="1">57 (35&#x02013;IC)</td><td valign="top" align="left" rowspan="1" colspan="1">84 (56&#x02013;IC)</td><td valign="top" align="left" rowspan="1" colspan="1">34 (22&#x02013;48)</td><td valign="top" align="left" rowspan="1" colspan="1">34 (28&#x02013;67)</td><td valign="top" align="left" rowspan="1" colspan="1">49 (37&#x02013;IC)</td><td valign="top" align="left" rowspan="1" colspan="1">56 (35&#x02013;70)</td><td valign="top" align="left" rowspan="1" colspan="1">36 (35&#x02013;42)</td><td valign="top" align="left" rowspan="1" colspan="1">29 (27&#x02013;35)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>=0.013</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>=0.001</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>=0.629</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>=0.061</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02265;30% reduction from baseline in
ADHD-RS-IV</td><td valign="top" align="left" rowspan="1" colspan="1">Number of participants</td><td valign="top" align="left" rowspan="1" colspan="1">28</td><td valign="top" align="left" rowspan="1" colspan="1">36</td><td valign="top" align="left" rowspan="1" colspan="1">37</td><td valign="top" align="left" rowspan="1" colspan="1">50</td><td valign="top" align="left" rowspan="1" colspan="1">38</td><td valign="top" align="left" rowspan="1" colspan="1">49</td><td valign="top" align="left" rowspan="1" colspan="1">198</td><td valign="top" align="left" rowspan="1" colspan="1">191</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">total score</td><td valign="top" align="left" rowspan="1" colspan="1">Median (95% CI), days</td><td valign="top" align="left" rowspan="1" colspan="1">28 (26&#x02013;43)</td><td valign="top" align="left" rowspan="1" colspan="1">36 (28&#x02013;56)</td><td valign="top" align="left" rowspan="1" colspan="1">21 (14&#x02013;27)</td><td valign="top" align="left" rowspan="1" colspan="1">25 (20&#x02013;33)</td><td valign="top" align="left" rowspan="1" colspan="1">28 (21&#x02013;33)</td><td valign="top" align="left" rowspan="1" colspan="1">28 (21&#x02013;35)</td><td valign="top" align="left" rowspan="1" colspan="1">23 (21&#x02013;27)</td><td valign="top" align="left" rowspan="1" colspan="1">20 (15&#x02013;21)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>=0.024</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>=0.006</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>=0.216</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>=0.042</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn28-ndt-12-1085"><p><bold>Note:</bold>
<italic>P</italic>-values from a log-rank test stratified by age-group
and country.</p></fn><fn id="tfn29-ndt-12-1085"><p><bold>Abbreviations:</bold> ADHD-RS-IV, Attention-Deficit/Hyperactivity
Disorder Rating Scale version IV; ATX, atomoxetine; CI, confidence
interval; GXR, guanfacine extended release; IC, incalculable; LOCF, last
observation carried forward; MPH, methylphenidate; RCT, randomized
controlled trial; RWS, randomized-withdrawal study.</p></fn></table-wrap-foot></table-wrap></supplementary-material><supplementary-material content-type="local-data" id="SD5-ndt-12-1085"><table-wrap id="ts4-ndt-12-1085" position="float"><label>Table S4</label><caption><p>CGI-S normal/borderline ill (CGI-S score of 1 or 2) and mildly ill or
greater (CGI-S score of &#x02265;3) at baseline and end point by treatment
for prior MPH or stimulant-na&#x000ef;ve subgroups (LOCF; full-analysis
set)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="4" valign="top" align="left" colspan="1">CGI-S</th><th colspan="6" valign="top" align="left" rowspan="1">RCT <hr/></th><th colspan="2" valign="top" align="left" rowspan="1">RWS <hr/></th></tr><tr><th colspan="2" valign="top" align="left" rowspan="1">Placebo (n=111)</th><th colspan="2" valign="top" align="left" rowspan="1">GXR (n=114)</th><th colspan="2" valign="top" align="left" rowspan="1">ATX (n=112)</th><th colspan="2" valign="top" align="left" rowspan="1">GXR (n=503)</th></tr><tr><th colspan="8" valign="top" align="left" rowspan="1">
<hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Prior MPH</th><th valign="top" align="left" rowspan="1" colspan="1">Stimulant-na&#x000ef;ve</th><th valign="top" align="left" rowspan="1" colspan="1">Prior MPH</th><th valign="top" align="left" rowspan="1" colspan="1">Stimulant-na&#x000ef;ve</th><th valign="top" align="left" rowspan="1" colspan="1">Prior MPH</th><th valign="top" align="left" rowspan="1" colspan="1">Stimulant-na&#x000ef;ve</th><th valign="top" align="left" rowspan="1" colspan="1">Prior MPH</th><th valign="top" align="left" rowspan="1" colspan="1">Stimulant-na&#x000ef;ve</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Baseline</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Number of participants</td><td valign="top" align="left" rowspan="1" colspan="1">48</td><td valign="top" align="left" rowspan="1" colspan="1">55</td><td valign="top" align="left" rowspan="1" colspan="1">46</td><td valign="top" align="left" rowspan="1" colspan="1">61</td><td valign="top" align="left" rowspan="1" colspan="1">48</td><td valign="top" align="left" rowspan="1" colspan="1">58</td><td valign="top" align="left" rowspan="1" colspan="1">224</td><td valign="top" align="left" rowspan="1" colspan="1">207</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Normal/borderline, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mildly ill or greater, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">48 (100)</td><td valign="top" align="left" rowspan="1" colspan="1">55 (100)</td><td valign="top" align="left" rowspan="1" colspan="1">46 (100)</td><td valign="top" align="left" rowspan="1" colspan="1">61 (100)</td><td valign="top" align="left" rowspan="1" colspan="1">48 (100)</td><td valign="top" align="left" rowspan="1" colspan="1">58 (100)</td><td valign="top" align="left" rowspan="1" colspan="1">224 (100)</td><td valign="top" align="left" rowspan="1" colspan="1">207 (100)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>End point</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Number of participants</td><td valign="top" align="left" rowspan="1" colspan="1">48</td><td valign="top" align="left" rowspan="1" colspan="1">55</td><td valign="top" align="left" rowspan="1" colspan="1">45</td><td valign="top" align="left" rowspan="1" colspan="1">60</td><td valign="top" align="left" rowspan="1" colspan="1">48</td><td valign="top" align="left" rowspan="1" colspan="1">58</td><td valign="top" align="left" rowspan="1" colspan="1">222</td><td valign="top" align="left" rowspan="1" colspan="1">206</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Normal/borderline, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">9 (18.8)</td><td valign="top" align="left" rowspan="1" colspan="1">15 (27.3)</td><td valign="top" align="left" rowspan="1" colspan="1">16 (35.6)</td><td valign="top" align="left" rowspan="1" colspan="1">24 (40.0)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (14.6)</td><td valign="top" align="left" rowspan="1" colspan="1">20 (34.5)</td><td valign="top" align="left" rowspan="1" colspan="1">152 (68.5)</td><td valign="top" align="left" rowspan="1" colspan="1">146 (70.9)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mildly ill or greater, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">39 (81.3)</td><td valign="top" align="left" rowspan="1" colspan="1">40 (72.7)</td><td valign="top" align="left" rowspan="1" colspan="1">29 (64.4)</td><td valign="top" align="left" rowspan="1" colspan="1">36 (60.0)</td><td valign="top" align="left" rowspan="1" colspan="1">41 (85.4)</td><td valign="top" align="left" rowspan="1" colspan="1">38 (65.5)</td><td valign="top" align="left" rowspan="1" colspan="1">70 (31.5)</td><td valign="top" align="left" rowspan="1" colspan="1">60 (29.1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Difference in % normal/borderline from
placebo (95% CI; <italic>P</italic>-value)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">16.8 (&#x02212;1.0 to 34.6;
<italic>P</italic>=0.070)</td><td valign="top" align="left" rowspan="1" colspan="1">12.7 (&#x02212;4.4 to 29.8;
<italic>P</italic>=0.073)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;4.2 (&#x02212;19.1 to 10.7;
<italic>P</italic>=0.516)</td><td valign="top" align="left" rowspan="1" colspan="1">7.2 (&#x02212;9.8 to 24.2;
<italic>P</italic>=0.242)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn30-ndt-12-1085"><p><bold>Note:</bold>
<italic>P</italic>-values based on
Cochran&#x02013;Mantel&#x02013;Haenszel statistic comparing the treatment
groups, with country and age-group included as stratification
factors.</p></fn><fn id="tfn31-ndt-12-1085"><p><bold>Abbreviations:</bold> ATX, atomoxetine; CGI-S, Clinical Global
Impression &#x02013; Severity scale; CI, confidence interval; GXR,
guanfacine extended release; LOCF, last observation carried forward; MPH,
methylphenidate; RCT, randomized controlled trial; RWS,
randomized-withdrawal study.</p></fn></table-wrap-foot></table-wrap></supplementary-material><supplementary-material content-type="local-data" id="SD6-ndt-12-1085"><table-wrap id="ts5-ndt-12-1085" position="float"><label>Table S5</label><caption><p>Combined responder analyses at end point for the RCT (ad hoc analyses; LOCF,
full-analysis set)</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Definition of response</th><th valign="top" align="left" rowspan="1" colspan="1">Response</th><th valign="top" align="left" rowspan="1" colspan="1">Placebo (n=111)</th><th valign="top" align="left" rowspan="1" colspan="1">GXR (n=114)</th><th valign="top" align="left" rowspan="1" colspan="1">ATX (n=112)</th></tr></thead><tbody><tr><td rowspan="3" valign="top" align="left" colspan="1">&#x02265;30% reduction from
baseline in ADHD-RS-IV and CGI-I score of 1 or 2</td><td valign="top" align="left" rowspan="1" colspan="1">Number of participants</td><td valign="top" align="left" rowspan="1" colspan="1">111</td><td valign="top" align="left" rowspan="1" colspan="1">112</td><td valign="top" align="left" rowspan="1" colspan="1">112</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Responders, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">47 (42.3)</td><td valign="top" align="left" rowspan="1" colspan="1">72 (64.3)</td><td valign="top" align="left" rowspan="1" colspan="1">62 (55.4)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Difference in % responders from placebo
(95% CI; <italic>P</italic>-value)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">21.9 (9.2&#x02013;34.7;
<italic>P</italic>&#x0003c;0.001)</td><td valign="top" align="left" rowspan="1" colspan="1">13.0 (0&#x02013;26.0;
<italic>P</italic>=0.017)</td></tr><tr><td rowspan="3" valign="top" align="left" colspan="1">&#x02265;50% reduction from
baseline in ADHD-RS-IV and CGI-I score of 1 or 2</td><td valign="top" align="left" rowspan="1" colspan="1">Number of participants</td><td valign="top" align="left" rowspan="1" colspan="1">111</td><td valign="top" align="left" rowspan="1" colspan="1">112</td><td valign="top" align="left" rowspan="1" colspan="1">112</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Responders, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">33 (29.7)</td><td valign="top" align="left" rowspan="1" colspan="1">60 (53.6)</td><td valign="top" align="left" rowspan="1" colspan="1">47 (42.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Difference in % responders from placebo
(95% CI; <italic>P</italic>-value)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">23.8 (11.3&#x02013;36.4;
<italic>P</italic>&#x0003c;0.001)</td><td valign="top" align="left" rowspan="1" colspan="1">12.2 (&#x02212;0.2 to 24.7;
<italic>P</italic>=0.018)</td></tr></tbody></table><table-wrap-foot><fn id="tfn32-ndt-12-1085"><p><bold>Abbreviations:</bold> ADHD-RS-IV, Attention-Deficit/Hyperactivity
Disorder Rating Scale version IV; ATX, atomoxetine; CGI-I, Clinical
Global Impression &#x02013; Improvement scale; CI, confidence interval;
GXR, guanfacine extended release; LOCF, last observation carried forward;
RCT, randomized controlled trial.</p></fn></table-wrap-foot></table-wrap></supplementary-material></sec></sec></body><back><ack><title>Acknowledgments</title><p>Research was funded by Shire Development LLC. Under the direction of the authors, Joanna
Wright, DPhil, CMPP and Jackie Marchington, PhD, CMPP, employees of Caudex, Oxford, UK,
and Eric Southam, PhD, CMPP, and Isabelle Kaufmann, PhD, employees of Oxford
PharmaGenesis, Oxford, UK, provided writing assistance for this publication. Editorial
assistance in formatting, proofreading, copy-editing, and fact-checking was also
provided by Caudex, Oxford, UK. Antonia Panayi of Shire International GmbH, Switzerland,
also reviewed and edited the manuscript for scientific accuracy. Vanja Sikirica and
Brigitte Robertson, employees of Shire Development LLC at the time of the study, and
Andrew Lyne and Ralph Bloomfield, employees of Shire Development Ltd. at the time of the
study, provided the statistical analyses and review for the publication. Shire
International GmbH, Switzerland provided funding to Caudex, Oxford, UK, and Oxford
Pharmagenesis, Oxford, UK for support in writing and editing this manuscript. Shire
manufactures and distributes drugs for the treatment of ADHD. Although employees of the
sponsor were involved in the design, collection, analysis, interpretation, and
fact-checking of information, the content of this manuscript, the interpretation of the
data, and the decision to submit the manuscript for publication in
<italic>Neuropsychiatric Disease and Treatment</italic> was made by the authors
independently.</p></ack><fn-group><fn><p><bold>Disclosure</bold></p><p>MH is a member of advisory boards and has spoken at educational events for Eli Lilly,
Janssen Cilag, Medice, Novartis, and Shire, and has received consultation fees from
Engelhard Arzneimittel, Medice, Shire, and Steiner Arzneimittel. AH has been on
advisory boards for Janssen, Eli Lilly, and Shire. JHN receives or has received
research grant support from Enzymotec and Shire. He is also a consultant and/or
advisor for Alcobra, Biobehavioral Diagnostics, Ironshore, Neos, NFL, Rhodes,
Sunovion, and Shire. VH has received research funding from Shire, Eli Lilly, and
Flynn Pharma, and has spoken at educational events sponsored by Shire, Eli Lilly,
Janssen Cilag, and Flynn Pharma. VS and BR were employees of Shire at the time of the
study.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-ndt-12-1085"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>National Institute for Health and Care Excellence</collab></person-group><source>Attention Deficit Hyperactivity Disorder: Diagnosis and
Management</source><publisher-loc>Manchester</publisher-loc><publisher-name>NICE</publisher-name><year>2008</year><comment>Available
from: <ext-link ext-link-type="uri" xlink:href="http://www.nice.org.uk/guidance/cg72/resources/attention-deficit-hyperactivity-disorder-diagnosis-and-management-975625063621">http://www.nice.org.uk/guidance/cg72/resources/attention-deficit-hyperactivity-disorder-diagnosis-and-management-975625063621</ext-link></comment><date-in-citation>Accessed
November 18, 2015</date-in-citation></element-citation></ref><ref id="b2-ndt-12-1085"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>E</given-names></name><name><surname>D&#x000f6;pfner</surname><given-names>M</given-names></name><name><surname>Sergeant</surname><given-names>J</given-names></name><etal/></person-group><article-title>European clinical guidelines for hyperkinetic disorder
&#x02013; first upgrade</article-title><source>Eur Child Adolesc
Psychiatry</source><year>2004</year><volume>13</volume><issue>Suppl
1</issue><fpage>I7</fpage><lpage>I30</lpage><pub-id pub-id-type="pmid">15322953</pub-id></element-citation></ref><ref id="b3-ndt-12-1085"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michelson</surname><given-names>D</given-names></name><name><surname>Allen</surname><given-names>AJ</given-names></name><name><surname>Busner</surname><given-names>J</given-names></name><etal/></person-group><article-title>Once-daily atomoxetine treatment for children and
adolescents with attention deficit hyperactivity disorder: a randomized,
placebo-controlled study</article-title><source>Am J
Psychiatry</source><year>2002</year><volume>159</volume><fpage>1896</fpage><lpage>1901</lpage><pub-id pub-id-type="pmid">12411225</pub-id></element-citation></ref><ref id="b4-ndt-12-1085"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biederman</surname><given-names>J</given-names></name><name><surname>Melmed</surname><given-names>RD</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><etal/></person-group><article-title>A randomized, double-blind, placebo-controlled study of
guanfacine extended release in children and adolescents with
attention-deficit/hyperactivity
disorder</article-title><source>Pediatrics</source><year>2008</year><volume>121</volume><fpage>e73</fpage><lpage>e84</lpage><pub-id pub-id-type="pmid">18166547</pub-id></element-citation></ref><ref id="b5-ndt-12-1085"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sallee</surname><given-names>FR</given-names></name><name><surname>McGough</surname><given-names>J</given-names></name><name><surname>Wigal</surname><given-names>T</given-names></name><name><surname>Donahue</surname><given-names>J</given-names></name><name><surname>Lyne</surname><given-names>A</given-names></name><name><surname>Biederman</surname><given-names>J</given-names></name></person-group><article-title>Guanfacine extended release in children and adolescents
with attention-deficit/hyperactivity disorder: a placebo-controlled
trial</article-title><source>J Am Acad Child Adolesc
Psychiatry</source><year>2009</year><volume>48</volume><fpage>155</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">19106767</pub-id></element-citation></ref><ref id="b6-ndt-12-1085"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodgkins</surname><given-names>P</given-names></name><name><surname>Shaw</surname><given-names>M</given-names></name><name><surname>Coghill</surname><given-names>D</given-names></name><name><surname>Hechtman</surname><given-names>L</given-names></name></person-group><article-title>Amfetamine and methylphenidate medications for
attention-deficit/hyperactivity disorder: complementary treatment
options</article-title><source>Eur Child Adolesc
Psychiatry</source><year>2012</year><volume>21</volume><fpage>477</fpage><lpage>492</lpage><pub-id pub-id-type="pmid">22763750</pub-id></element-citation></ref><ref id="b7-ndt-12-1085"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnsten</surname><given-names>AF</given-names></name><name><surname>Jin</surname><given-names>LE</given-names></name></person-group><article-title>Guanfacine for the treatment of cognitive disorders: a
century of discoveries at Yale</article-title><source>Yale J Biol
Med</source><year>2012</year><volume>85</volume><fpage>45</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">22461743</pub-id></element-citation></ref><ref id="b8-ndt-12-1085"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uhl&#x000e9;n</surname><given-names>S</given-names></name><name><surname>Wikberg</surname><given-names>JE</given-names></name></person-group><article-title>Delineation of rat kidney &#x003b1;2A- and
&#x003b1;2B-adrenoceptors with [<sup>3</sup>H]RX821002 radioligand
binding: computer modelling reveals that guanfacine is an &#x003b1;2A-selective
compound</article-title><source>Eur J
Pharmacol</source><year>1991</year><volume>202</volume><fpage>235</fpage><lpage>243</lpage><pub-id pub-id-type="pmid">1666366</pub-id></element-citation></ref><ref id="b9-ndt-12-1085"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malhotra</surname><given-names>PA</given-names></name><name><surname>Parton</surname><given-names>AD</given-names></name><name><surname>Greenwood</surname><given-names>R</given-names></name><name><surname>Husain</surname><given-names>M</given-names></name></person-group><article-title>Noradrenergic modulation of space exploration in visual
neglect</article-title><source>Ann
Neurol</source><year>2006</year><volume>59</volume><fpage>186</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">16261567</pub-id></element-citation></ref><ref id="b10-ndt-12-1085"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>KP</given-names></name><name><surname>Clerkin</surname><given-names>SM</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Halperin</surname><given-names>JM</given-names></name><name><surname>Newcorn</surname><given-names>JH</given-names></name></person-group><article-title>Guanfacine modulates the influence of emotional cues on
prefrontal cortex activation for cognitive
control</article-title><source>Psychopharmacology
(Berl)</source><year>2013</year><volume>226</volume><fpage>261</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">23086020</pub-id></element-citation></ref><ref id="b11-ndt-12-1085"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh-Curry</surname><given-names>V</given-names></name><name><surname>Malhotra</surname><given-names>P</given-names></name><name><surname>Farmer</surname><given-names>SF</given-names></name><name><surname>Husain</surname><given-names>M</given-names></name></person-group><article-title>Attention deficits following ADEM ameliorated by
guanfacine</article-title><source>J Neurol Neurosurg
Psychiatry</source><year>2011</year><volume>82</volume><fpage>688</fpage><lpage>690</lpage><pub-id pub-id-type="pmid">20562462</pub-id></element-citation></ref><ref id="b12-ndt-12-1085"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Ramos</surname><given-names>BP</given-names></name><name><surname>Paspalas</surname><given-names>CD</given-names></name><etal/></person-group><article-title>&#x003b1;2A-adrenoceptors strengthen working memory
networks by inhibiting cAMP-HCN channel signaling in prefrontal
cortex</article-title><source>Cell</source><year>2007</year><volume>129</volume><fpage>397</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">17448997</pub-id></element-citation></ref><ref id="b13-ndt-12-1085"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilens</surname><given-names>TE</given-names></name><name><surname>Bukstein</surname><given-names>O</given-names></name><name><surname>Brams</surname><given-names>M</given-names></name><etal/></person-group><article-title>A controlled trial of extended-release guanfacine and
psychostimulants for attention-deficit/hyperactivity
disorder</article-title><source>J Am Acad Child Adolesc
Psychiatry</source><year>2012</year><volume>51</volume><fpage>74</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">22176941</pub-id></element-citation></ref><ref id="b14-ndt-12-1085"><label>14</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Shire receives European approval for INTUNIV&#x000ae;</collab></person-group><source>guanfacine hydrochloride prolonged release tablets) as a
non-stimulant ADHD treatment for children and adolescents [press
release]</source><publisher-name>Shire</publisher-name><year>2015</year><comment>[September
21]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.shire.com/newsroom/2015/september/non-stimulant-for-adhd-approved-in-europe">https://www.shire.com/newsroom/2015/september/non-stimulant-for-adhd-approved-in-europe</ext-link></comment><date-in-citation>Accessed
November 30, 2015</date-in-citation></element-citation></ref><ref id="b15-ndt-12-1085"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bymaster</surname><given-names>FP</given-names></name><name><surname>Katner</surname><given-names>JS</given-names></name><name><surname>Nelson</surname><given-names>DL</given-names></name><etal/></person-group><article-title>Atomoxetine increases extracellular levels of
norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for
efficacy in attention deficit/hyperactivity
disorder</article-title><source>Neuropsychopharmacology</source><year>2002</year><volume>27</volume><fpage>699</fpage><lpage>711</lpage><pub-id pub-id-type="pmid">12431845</pub-id></element-citation></ref><ref id="b16-ndt-12-1085"><label>16</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Strattera [summary of product characteristics]</collab></person-group><publisher-loc>Basingstoke</publisher-loc><publisher-name>Eli Lilly
and Co</publisher-name><year>2015</year><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.medicines.org.uk/emc/medicine/14482">http://www.medicines.org.uk/emc/medicine/14482</ext-link></comment><date-in-citation>Accessed
July 30, 2015</date-in-citation></element-citation></ref><ref id="b17-ndt-12-1085"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newcorn</surname><given-names>JH</given-names></name><name><surname>Kratochvil</surname><given-names>CJ</given-names></name><name><surname>Allen</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Atomoxetine and osmotically released methylphenidate
for the treatment of attention deficit hyperactivity disorder: acute comparison
and differential response</article-title><source>Am J
Psychiatry</source><year>2008</year><volume>165</volume><fpage>721</fpage><lpage>730</lpage><pub-id pub-id-type="pmid">18281409</pub-id></element-citation></ref><ref id="b18-ndt-12-1085"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>S</given-names></name><name><surname>Correll</surname><given-names>CU</given-names></name></person-group><article-title>Efficacy and safety of atomoxetine in children and
adolescents with attention-deficit/hyperactivity disorder: results from a
comprehensive meta-analysis and metaregression</article-title><source>J Am Acad
Child Adolesc
Psychiatry</source><year>2014</year><volume>53</volume><fpage>174</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">24472252</pub-id></element-citation></ref><ref id="b19-ndt-12-1085"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hervas</surname><given-names>A</given-names></name><name><surname>Huss</surname><given-names>M</given-names></name><name><surname>Johnson</surname><given-names>M</given-names></name><etal/></person-group><article-title>Efficacy and safety of extended-release guanfacine
hydrochloride in children and adolescents with attention-deficit/hyperactivity
disorder: a randomized, controlled, phase III trial</article-title><source>Eur
Neuropsychopharmacol</source><year>2014</year><volume>24</volume><fpage>1861</fpage><lpage>1872</lpage><pub-id pub-id-type="pmid">25453486</pub-id></element-citation></ref><ref id="b20-ndt-12-1085"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newcorn</surname><given-names>J</given-names></name><name><surname>Harpin</surname><given-names>V</given-names></name><name><surname>Huss</surname><given-names>M</given-names></name><etal/></person-group><article-title>Extended-release guanfacine hydrochloride in
6&#x02013;17-year-olds with ADHD: A randomized-withdrawal maintenance of efficacy
study</article-title><source>J Child Psychol
Psychiatry</source><comment>Epub</comment><year>2016</year><month>2</month><day>12</day></element-citation></ref><ref id="b21-ndt-12-1085"><label>21</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Shire</collab></person-group><source>Maintenance of efficacy of extended-release guanfacine HCl in
children and adolescents with attention-deficit/hyperactivity disorder
(ADHD)</source><comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01081145">https://clinicaltrials.gov/ct2/show/NCT01081145</ext-link>.
NLM identifier: NCT01081145</comment><date-in-citation>Accessed November 18,
2015</date-in-citation></element-citation></ref><ref id="b22-ndt-12-1085"><label>22</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>European Medicines Agency</collab></person-group><source>Guideline on the clinical investigation of medicinal products
for the treatment of attention deficit hyperactivity disorder
(ADHD)</source><year>2010</year><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/08/WC500095686.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/08/WC500095686.pdf</ext-link></comment><date-in-citation>Accessed
July 30, 2015</date-in-citation></element-citation></ref><ref id="b23-ndt-12-1085"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berridge</surname><given-names>CW</given-names></name><name><surname>Devilbiss</surname><given-names>DM</given-names></name><name><surname>Andrzejewski</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Methylphenidate preferentially increases catecholamine
neurotransmission within the prefrontal cortex at low doses that enhance cognitive
function</article-title><source>Biol
Psychiatry</source><year>2006</year><volume>60</volume><fpage>1111</fpage><lpage>1120</lpage><pub-id pub-id-type="pmid">16806100</pub-id></element-citation></ref><ref id="b24-ndt-12-1085"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Easton</surname><given-names>N</given-names></name><name><surname>Steward</surname><given-names>C</given-names></name><name><surname>Marshall</surname><given-names>F</given-names></name><name><surname>Fone</surname><given-names>K</given-names></name><name><surname>Marsden</surname><given-names>C</given-names></name></person-group><article-title>Effects of amphetamine isomers, methylphenidate and
atomoxetine on synaptosomal and synaptic vesicle accumulation and release of
dopamine and noradrenaline in vitro in the rat
brain</article-title><source>Neuropharmacology</source><year>2007</year><volume>52</volume><fpage>405</fpage><lpage>414</lpage><pub-id pub-id-type="pmid">17020775</pub-id></element-citation></ref><ref id="b25-ndt-12-1085"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>GJ</given-names></name><name><surname>Volkow</surname><given-names>ND</given-names></name><name><surname>Wigal</surname><given-names>T</given-names></name><etal/></person-group><article-title>Long-term stimulant treatment affects brain dopamine
transporter level in patients with attention deficit hyperactive
disorder</article-title><source>PLoS
One</source><year>2013</year><volume>8</volume><fpage>e63023</fpage><pub-id pub-id-type="pmid">23696790</pub-id></element-citation></ref><ref id="b26-ndt-12-1085"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fusar-Poli</surname><given-names>P</given-names></name><name><surname>Rubia</surname><given-names>K</given-names></name><name><surname>Rossi</surname><given-names>G</given-names></name><name><surname>Sartori</surname><given-names>G</given-names></name><name><surname>Balottin</surname><given-names>U</given-names></name></person-group><article-title>Striatal dopamine transporter alterations in ADHD:
pathophysiology or adaptation to psychostimulants? A
meta-analysis</article-title><source>Am J
Psychiatry</source><year>2012</year><volume>169</volume><fpage>264</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">22294258</pub-id></element-citation></ref><ref id="b27-ndt-12-1085"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>KA</given-names></name><name><surname>Barry</surname><given-names>E</given-names></name><name><surname>Lambert</surname><given-names>D</given-names></name><etal/></person-group><article-title>Methylphenidate side effect profile is influenced by
genetic variation in the attention-deficit/hyperactivity disorder-associated CES1
gene</article-title><source>J Child Adolesc
Psychopharmacol</source><year>2013</year><volume>23</volume><fpage>655</fpage><lpage>664</lpage><pub-id pub-id-type="pmid">24350812</pub-id></element-citation></ref><ref id="b28-ndt-12-1085"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roman</surname><given-names>T</given-names></name><name><surname>Rohde</surname><given-names>LA</given-names></name><name><surname>Hutz</surname><given-names>MH</given-names></name></person-group><article-title>Polymorphisms of the dopamine transporter gene:
influence on response to methylphenidate in attention deficit-hyperactivity
disorder</article-title><source>Am J
Pharmacogenomics</source><year>2004</year><volume>4</volume><fpage>83</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">15059031</pub-id></element-citation></ref><ref id="b29-ndt-12-1085"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coghill</surname><given-names>DR</given-names></name><name><surname>Banaschewski</surname><given-names>T</given-names></name><name><surname>Lecendreux</surname><given-names>M</given-names></name><etal/></person-group><article-title>Post hoc analyses of the impact of previous medication
on the efficacy of lisdexamfetamine dimesylate in the treatment of
attention-deficit/hyperactivity disorder in a randomized, controlled
trial</article-title><source>Neuropsychiatr Dis
Treat</source><year>2014</year><volume>10</volume><fpage>2039</fpage><lpage>2047</lpage><pub-id pub-id-type="pmid">25378930</pub-id></element-citation></ref><ref id="b30-ndt-12-1085"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dittmann</surname><given-names>RW</given-names></name><name><surname>Cardo</surname><given-names>E</given-names></name><name><surname>Nagy</surname><given-names>P</given-names></name><etal/></person-group><article-title>Treatment response and remission in a double-blind,
randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in
children and adolescents with attention-deficit hyperactivity
disorder</article-title><source>CNS
Drugs</source><year>2014</year><volume>28</volume><fpage>1059</fpage><lpage>1069</lpage><pub-id pub-id-type="pmid">25038977</pub-id></element-citation></ref><ref id="b31-ndt-12-1085"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>R</given-names></name><name><surname>Babcock</surname><given-names>T</given-names></name><name><surname>Burtea</surname><given-names>T</given-names></name><etal/></person-group><article-title>Efficacy of lisdexamfetamine dimesylate in children
with attention-deficit/hyperactivity disorder previously treated with
methylphenidate: a post hoc analysis</article-title><source>Child Adolesc
Psychiatry Ment
Health</source><year>2011</year><volume>5</volume><fpage>35</fpage><pub-id pub-id-type="pmid">22054243</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-ndt-12-1085" position="float"><label>Figure 1</label><caption><p>Participant disposition in the randomized controlled trial and open-label phase of
the randomized-withdrawal study.</p><p><bold>Notes:</bold>
<sup>a</sup>Excludes participants from site 801 (due to breach of good clinical
practice that was reported to applicable authorities). <sup>b</sup>Includes
participants who were treatment-na&#x000ef;ve or who reported prior use of
non-stimulant ADHD medications. <sup>c</sup>One participant was excluded from the
efficacy analyses due to no available post-baseline measurements.
<sup>d</sup>Three participants were excluded from the ADHD-RS-IV efficacy
analyses, and two participants were excluded from the CGI-I efficacy analyses due
to no available post-baseline measurements. Based on responses in the Prior
Stimulant Medication Questionnaire, participants were categorized as either
stimulant-na&#x000ef;ve or having received any prior stimulant. Those who had
received stimulants were grouped by the type of the most recent stimulant (ie,
last stimulant received prior to the 3- to 35-day washout/screening period). The
efficacies of GXR and ATX versus placebo were compared in participants who had
received prior MPH and stimulant-na&#x000ef;ve (gray shading).</p><p><bold>Abbreviations:</bold> ADHD, attention-deficit/hyperactivity disorder;
ADHD-RS-IV, ADHD Rating Scale version IV; ATX, atomoxetine; CGI-I, Clinical Global
Impression &#x02013; Improvement scale; FAS, full-analysis set; GXR, guanfacine
extended release; MPH, methylphenidate; OL, open-label; RCT, randomized controlled
trial; RWS, randomized-withdrawal study.</p></caption><graphic xlink:href="ndt-12-1085Fig1"/></fig><fig id="f2-ndt-12-1085" position="float"><label>Figure 2</label><caption><p>Mean change from baseline in ADHD-RS-IV total score by treatment for prior MPH or
stimulant-na&#x000ef;ve subgroups at endpoint (full-analysis set).</p><p><bold>Notes:</bold> *<italic>P</italic>&#x0003c;0.05;
**<italic>P</italic>&#x0003c;0.001 versus placebo. Nominal
statistical differences based on ANCOVA of placebo-adjusted LS means in the RCT
only. Statistics not performed for RWS. Not all patients had ADHD-RS-IV total
score data available at end point.</p><p><bold>Abbreviations:</bold> ADHD-RS-IV, ADHD Rating Scale version IV; ANCOVA,
analysis of covariance; ATX, atomoxetine; GXR, guanfacine extended release; LOCF,
last observation carried forward; LS, least squares; MPH, methylphenidate; RCT,
randomized controlled trial; RWS, randomized-withdrawal study.</p></caption><graphic xlink:href="ndt-12-1085Fig2"/></fig><fig id="f3-ndt-12-1085" position="float"><label>Figure 3</label><caption><p>Proportion of participants with improved (%) CGI-I (scores of 1 or 2), at end
point, by treatment in prior MPH or stimulant-na&#x000ef;ve subgroups (LOCF;
full-analysis set).</p><p><bold>Notes:</bold> *<italic>P</italic>=0.005;
**<italic>P</italic>&#x0003c;0.001 versus placebo; error bars
represent 95% confidence intervals. Improved includes CGI-I categories
&#x0201c;very much improved&#x0201d; and &#x0201c;much improved&#x0201d;.</p><p><bold>Abbreviations:</bold> ATX, atomoxetine; CGI-I, Clinical Global Impression
&#x02013; Improvement scale; GXR, guanfacine extended release; LOCF, last
observation carried forward; MPH, methylphenidate; RCT, randomized controlled
trial; RWS, randomized-withdrawal study.</p></caption><graphic xlink:href="ndt-12-1085Fig3"/></fig><table-wrap id="t1-ndt-12-1085" position="float"><label>Table 1</label><caption><p>Summary of prior stimulant medications</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="top" align="left" colspan="1">Prior ADHD medication used</th><th colspan="4" valign="top" align="left" rowspan="1">RCT <hr/></th><th valign="top" align="left" rowspan="1" colspan="1">RWS <hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Placebo (n=111)</th><th valign="top" align="left" rowspan="1" colspan="1">GXR (n=114)</th><th valign="top" align="left" rowspan="1" colspan="1">ATX (n=112)</th><th valign="top" align="left" rowspan="1" colspan="1">Total (n=337)</th><th valign="top" align="left" rowspan="1" colspan="1">GXR (n=503)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Prior MPH use, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">48 (43.2)</td><td valign="top" align="left" rowspan="1" colspan="1">46 (40.4)</td><td valign="top" align="left" rowspan="1" colspan="1">48 (42.9)</td><td valign="top" align="left" rowspan="1" colspan="1">142 (42.1)</td><td valign="top" align="left" rowspan="1" colspan="1">224 (44.5)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;MPH, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">45 (40.5)</td><td valign="top" align="left" rowspan="1" colspan="1">46 (40.4)</td><td valign="top" align="left" rowspan="1" colspan="1">47 (42.0)</td><td valign="top" align="left" rowspan="1" colspan="1">138 (40.9)</td><td valign="top" align="left" rowspan="1" colspan="1">205 (40.8)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Dexmethylphenidate, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (2.7)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">1 (0.9)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (1.2)</td><td valign="top" align="left" rowspan="1" colspan="1">19 (3.8)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Prior non-MPH use, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">8 (7.2)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (6.1)</td><td valign="top" align="left" rowspan="1" colspan="1">6 (5.4)</td><td valign="top" align="left" rowspan="1" colspan="1">21 (6.2)</td><td valign="top" align="left" rowspan="1" colspan="1">72 (14.3)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Mixed amphetamine salts, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (2.7)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (1.7)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (2.6)</td><td valign="top" align="left" rowspan="1" colspan="1">8 (2.4)</td><td valign="top" align="left" rowspan="1" colspan="1">30 (6.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Amphetamine, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (0.9)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">2 (1.8)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (0.9)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (0.2)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Dextroamphetamine, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (0.9)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">1 (0.3)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (0.4)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Lisdexamfetamine, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (2.7)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (4.4)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (0.9)</td><td valign="top" align="left" rowspan="1" colspan="1">9 (2.7)</td><td valign="top" align="left" rowspan="1" colspan="1">39 (7.7)</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-ndt-12-1085"><p><bold>Note:</bold> Prior stimulant medication as named by participants in the
Prior Stimulant Medication Questionnaire.</p></fn><fn id="tfn2-ndt-12-1085"><p><bold>Abbreviations:</bold> ADHD, attention-deficit/hyperactivity disorder;
ATX, atomoxetine; GXR, guanfacine extended release; MPH, methylphenidate; RCT,
randomized controlled trial; RWS, randomized-withdrawal study.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-ndt-12-1085" position="float"><label>Table 2</label><caption><p>Participant baseline characteristics and demographic data from the RCT (safety
population/full-analysis set) and the RWS (safety population), according to prior
stimulant-medication status</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="5" valign="top" align="left" colspan="1">Characteristic</th><th colspan="6" valign="top" align="left" rowspan="1">RCT <hr/></th><th colspan="2" valign="top" align="left" rowspan="1">RWS <hr/></th></tr><tr><th colspan="2" valign="top" align="left" rowspan="1">Placebo (n=111) <hr/></th><th colspan="2" valign="top" align="left" rowspan="1">GXR (n=114) <hr/></th><th colspan="2" valign="top" align="left" rowspan="1">ATX (n=112) <hr/></th><th colspan="2" valign="top" align="left" rowspan="1">n=526<xref ref-type="table-fn" rid="tfn3-ndt-12-1085">a</xref>
<hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Prior MPH</th><th valign="top" align="left" rowspan="1" colspan="1">Stimulant-na&#x000ef;ve</th><th valign="top" align="left" rowspan="1" colspan="1">Prior MPH</th><th valign="top" align="left" rowspan="1" colspan="1">Stimulant-na&#x000ef;ve</th><th valign="top" align="left" rowspan="1" colspan="1">Prior MPH</th><th valign="top" align="left" rowspan="1" colspan="1">Stimulant-na&#x000ef;ve</th><th valign="top" align="left" rowspan="1" colspan="1">Prior MPH</th><th valign="top" align="left" rowspan="1" colspan="1">Stimulant-na&#x000ef;ve</th></tr><tr><th colspan="8" valign="top" align="left" rowspan="1">
<hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">n=48</th><th valign="top" align="left" rowspan="1" colspan="1">n=55</th><th valign="top" align="left" rowspan="1" colspan="1">n=46</th><th valign="top" align="left" rowspan="1" colspan="1">n=61</th><th valign="top" align="left" rowspan="1" colspan="1">n=48</th><th valign="top" align="left" rowspan="1" colspan="1">n=58</th><th valign="top" align="left" rowspan="1" colspan="1">n=227</th><th valign="top" align="left" rowspan="1" colspan="1">n=227</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (years), mean (SD)</td><td valign="top" align="left" rowspan="1" colspan="1">11.0 (2.32)</td><td valign="top" align="left" rowspan="1" colspan="1">10.7 (3.04)</td><td valign="top" align="left" rowspan="1" colspan="1">11.5 (2.52)</td><td valign="top" align="left" rowspan="1" colspan="1">10.4 (2.97)</td><td valign="top" align="left" rowspan="1" colspan="1">10.8 (2.79)</td><td valign="top" align="left" rowspan="1" colspan="1">10.3 (2.86)</td><td valign="top" align="left" rowspan="1" colspan="1">10.9 (2.52)</td><td valign="top" align="left" rowspan="1" colspan="1">10.1 (2.76)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Male, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">41 (85.4)</td><td valign="top" align="left" rowspan="1" colspan="1">42 (76.4)</td><td valign="top" align="left" rowspan="1" colspan="1">33 (71.7)</td><td valign="top" align="left" rowspan="1" colspan="1">39 (63.9)</td><td valign="top" align="left" rowspan="1" colspan="1">42 (87.5)</td><td valign="top" align="left" rowspan="1" colspan="1">41 (70.7)</td><td valign="top" align="left" rowspan="1" colspan="1">173 (76.2)</td><td valign="top" align="left" rowspan="1" colspan="1">163 (71.8)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>), mean (SD)</td><td valign="top" align="left" rowspan="1" colspan="1">18.29 (2.48)</td><td valign="top" align="left" rowspan="1" colspan="1">19.08 (2.85)</td><td valign="top" align="left" rowspan="1" colspan="1">18.52 (3.11)</td><td valign="top" align="left" rowspan="1" colspan="1">18.81 (2.93)</td><td valign="top" align="left" rowspan="1" colspan="1">18.71 (3.12)</td><td valign="top" align="left" rowspan="1" colspan="1">18.77 (2.86)</td><td valign="top" align="left" rowspan="1" colspan="1">18.38 (2.84)</td><td valign="top" align="left" rowspan="1" colspan="1">18.98 (2.85)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ADHD subtype, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Predominantly inattentive</td><td valign="top" align="left" rowspan="1" colspan="1">3 (6.3)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (12.7)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (21.7)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (4.9)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (8.3)</td><td valign="top" align="left" rowspan="1" colspan="1">6 (10.3)</td><td valign="top" align="left" rowspan="1" colspan="1">28 (12.3)</td><td valign="top" align="left" rowspan="1" colspan="1">31 (13.7)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Predominantly
hyperactive&#x02013;impulsive</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2.1)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (7.3)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2.2)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (8.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">3 (5.2)</td><td valign="top" align="left" rowspan="1" colspan="1">11 (4.8)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (3.1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Combined</td><td valign="top" align="left" rowspan="1" colspan="1">44 (91.7)</td><td valign="top" align="left" rowspan="1" colspan="1">44 (80.0)</td><td valign="top" align="left" rowspan="1" colspan="1">35 (76.1)</td><td valign="top" align="left" rowspan="1" colspan="1">53 (86.9)</td><td valign="top" align="left" rowspan="1" colspan="1">44 (91.7)</td><td valign="top" align="left" rowspan="1" colspan="1">49 (84.5)</td><td valign="top" align="left" rowspan="1" colspan="1">188 (82.8)</td><td valign="top" align="left" rowspan="1" colspan="1">189 (83.3)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Baseline ADHD-RS-IV score, mean (SD)</td><td valign="top" align="left" rowspan="1" colspan="1">43.7 (5.34)</td><td valign="top" align="left" rowspan="1" colspan="1">42.7 (5.71)</td><td valign="top" align="left" rowspan="1" colspan="1">43.5 (5.44)</td><td valign="top" align="left" rowspan="1" colspan="1">42.7 (5.57)</td><td valign="top" align="left" rowspan="1" colspan="1">44.7 (5.55)</td><td valign="top" align="left" rowspan="1" colspan="1">42.7 (5.98)</td><td valign="top" align="left" rowspan="1" colspan="1">45.1 (6.02)</td><td valign="top" align="left" rowspan="1" colspan="1">42.7 (6.39)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Baseline CGI-S, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Moderately ill</td><td valign="top" align="left" rowspan="1" colspan="1">11 (22.9)</td><td valign="top" align="left" rowspan="1" colspan="1">18 (32.7)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (6.5)</td><td valign="top" align="left" rowspan="1" colspan="1">17 (27.9)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (6.3)</td><td valign="top" align="left" rowspan="1" colspan="1">17 (29.3)</td><td valign="top" align="left" rowspan="1" colspan="1">35 (15.4)</td><td valign="top" align="left" rowspan="1" colspan="1">60 (26.4)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Markedly ill</td><td valign="top" align="left" rowspan="1" colspan="1">18 (37.5)</td><td valign="top" align="left" rowspan="1" colspan="1">28 (50.9)</td><td valign="top" align="left" rowspan="1" colspan="1">21 (45.7)</td><td valign="top" align="left" rowspan="1" colspan="1">34 (55.7)</td><td valign="top" align="left" rowspan="1" colspan="1">25 (52.1)</td><td valign="top" align="left" rowspan="1" colspan="1">28 (48.3)</td><td valign="top" align="left" rowspan="1" colspan="1">103 (45.4)</td><td valign="top" align="left" rowspan="1" colspan="1">123 (54.2)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Severely ill</td><td valign="top" align="left" rowspan="1" colspan="1">18 (37.5)</td><td valign="top" align="left" rowspan="1" colspan="1">8 (14.5)</td><td valign="top" align="left" rowspan="1" colspan="1">19 (41.3)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (16.4)</td><td valign="top" align="left" rowspan="1" colspan="1">18 (37.5)</td><td valign="top" align="left" rowspan="1" colspan="1">13 (22.4)</td><td valign="top" align="left" rowspan="1" colspan="1">66 (29.1)</td><td valign="top" align="left" rowspan="1" colspan="1">41 (18.1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Among the most extremely ill</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2.1)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (1.8)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (6.5)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">2 (4.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">23 (10.1)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (1.3)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Baseline CPRS-R:L oppositional subscale score,
mean (SD)</td><td valign="top" align="left" rowspan="1" colspan="1">15.0 (7.22)</td><td valign="top" align="left" rowspan="1" colspan="1">13.3 (6.85)</td><td valign="top" align="left" rowspan="1" colspan="1">14.8 (7.92)</td><td valign="top" align="left" rowspan="1" colspan="1">13.0 (6.47)</td><td valign="top" align="left" rowspan="1" colspan="1">16.3 (7.00)</td><td valign="top" align="left" rowspan="1" colspan="1">14.4 (7.20)</td><td valign="top" align="left" rowspan="1" colspan="1">16.5 (7.96)</td><td valign="top" align="left" rowspan="1" colspan="1">15.5 (7.42)</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold></p></fn><fn id="tfn3-ndt-12-1085"><label>a</label><p>The safety population for the RWS comprised 526 participants, of whom 503 were
included in the full-analysis set. Percentages based on the number of
participants in each subgroup for each treatment. Participants who received
prior non-MPH treatment not included in this table.</p></fn><fn id="tfn4-ndt-12-1085"><p><bold>Abbreviations:</bold> ADHD, attention-deficit/hyperactivity disorder;
ADHD-RS-IV, ADHD Rating Scale version IV; ATX, atomoxetine; BMI, body mass
index; CGI-S, Clinical Global Impression &#x02013; Severity scale; CPRS-R:L,
Conners Parent Rating Scales &#x02013; revised: long; GXR, guanfacine extended
release; MPH, methylphenidate; RCT, randomized controlled trial; RWS,
randomized-withdrawal study; SD, standard deviation.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-ndt-12-1085" position="float"><label>Table 3</label><caption><p>Summary of reasons for stopping prior MPH treatment, by treatment (full-analysis
set)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="top" align="left" colspan="1">Reason for stopping prior MPH, n
(%)<xref ref-type="table-fn" rid="tfn6-ndt-12-1085">a</xref></th><th colspan="4" valign="top" align="left" rowspan="1">RCT <hr/></th><th valign="top" align="left" rowspan="1" colspan="1">RWS <hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Placebo<break/>(n=111)</th><th valign="top" align="left" rowspan="1" colspan="1">GXR<break/>(n=114)</th><th valign="top" align="left" rowspan="1" colspan="1">ATX<break/>(n=112)</th><th valign="top" align="left" rowspan="1" colspan="1">Total<break/>(n=337)</th><th valign="top" align="left" rowspan="1" colspan="1">GXR<break/>(n=503)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Number of participants (n)</td><td valign="top" align="left" rowspan="1" colspan="1">48</td><td valign="top" align="left" rowspan="1" colspan="1">46</td><td valign="top" align="left" rowspan="1" colspan="1">48</td><td valign="top" align="left" rowspan="1" colspan="1">142</td><td valign="top" align="left" rowspan="1" colspan="1">224</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Not effective</td><td valign="top" align="left" rowspan="1" colspan="1">28 (58.3)</td><td valign="top" align="left" rowspan="1" colspan="1">25 (54.3)</td><td valign="top" align="left" rowspan="1" colspan="1">27 (56.3)</td><td valign="top" align="left" rowspan="1" colspan="1">80 (56.3)</td><td valign="top" align="left" rowspan="1" colspan="1">145 (64.7)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Did not work</td><td valign="top" align="left" rowspan="1" colspan="1">7 (14.6)</td><td valign="top" align="left" rowspan="1" colspan="1">6 (13.0)</td><td valign="top" align="left" rowspan="1" colspan="1">9 (18.8)</td><td valign="top" align="left" rowspan="1" colspan="1">22 (15.5)</td><td valign="top" align="left" rowspan="1" colspan="1">28 (12.5)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Effect did not last long enough</td><td valign="top" align="left" rowspan="1" colspan="1">7 (14.6)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (15.2)</td><td valign="top" align="left" rowspan="1" colspan="1">9 (18.8)</td><td valign="top" align="left" rowspan="1" colspan="1">23 (16.2)</td><td valign="top" align="left" rowspan="1" colspan="1">40 (17.9)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Was not optimal per the
participant/parent/caregiver</td><td valign="top" align="left" rowspan="1" colspan="1">19 (39.6)</td><td valign="top" align="left" rowspan="1" colspan="1">18 (39.1)</td><td valign="top" align="left" rowspan="1" colspan="1">18 (37.5)</td><td valign="top" align="left" rowspan="1" colspan="1">55 (38.7)</td><td valign="top" align="left" rowspan="1" colspan="1">91 (40.6)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Was not optimal per the
participant&#x02019;s physician</td><td valign="top" align="left" rowspan="1" colspan="1">8 (16.7)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (15.2)</td><td valign="top" align="left" rowspan="1" colspan="1">14 (29.2)</td><td valign="top" align="left" rowspan="1" colspan="1">29 (20.4)</td><td valign="top" align="left" rowspan="1" colspan="1">31 (13.8)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Other</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2.1)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (4.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">3 (2.1)</td><td valign="top" align="left" rowspan="1" colspan="1">13 (5.8)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Because the ADHD medication had side effects</td><td valign="top" align="left" rowspan="1" colspan="1">18 (37.5)</td><td valign="top" align="left" rowspan="1" colspan="1">18 (39.1)</td><td valign="top" align="left" rowspan="1" colspan="1">17 (35.4)</td><td valign="top" align="left" rowspan="1" colspan="1">53 (37.3)</td><td valign="top" align="left" rowspan="1" colspan="1">122 (54.5)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Wanted to switch to another medication</td><td valign="top" align="left" rowspan="1" colspan="1">15 (31.3)</td><td valign="top" align="left" rowspan="1" colspan="1">15 (32.6)</td><td valign="top" align="left" rowspan="1" colspan="1">11 (22.9)</td><td valign="top" align="left" rowspan="1" colspan="1">41 (28.9)</td><td valign="top" align="left" rowspan="1" colspan="1">12 (5.4)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Wanted to stop taking MPH</td><td valign="top" align="left" rowspan="1" colspan="1">7 (14.6)</td><td valign="top" align="left" rowspan="1" colspan="1">8 (17.4)</td><td valign="top" align="left" rowspan="1" colspan="1">9 (18.8)</td><td valign="top" align="left" rowspan="1" colspan="1">24 (16.9)</td><td valign="top" align="left" rowspan="1" colspan="1">25 (11.2)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Could not afford to pay for medication</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2.1)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (8.7)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2.1)</td><td valign="top" align="left" rowspan="1" colspan="1">6 (4.2)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (4.5)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Wanted to stop taking any ADHD medication</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">2 (4.3)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (4.2)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (2.8)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (0.4)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Wanted to switch to nonpharmacological
interventions to treat ADHD</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Other</td><td valign="top" align="left" rowspan="1" colspan="1">1 (2.1)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">1 (0.7)</td><td valign="top" align="left" rowspan="1" colspan="1">13 (5.8)</td></tr></tbody></table><table-wrap-foot><fn id="tfn5-ndt-12-1085"><p><bold>Notes:</bold> Reasons for stopping previous MPH treatment were recorded
in the Prior Stimulant Medication Questionnaire.</p></fn><fn id="tfn6-ndt-12-1085"><label>a</label><p>Categories not mutually exclusive; therefore, columns may total &#x0003e;100%.
Includes participants who took prior MPH, as confirmed by medical review of
medication names provided in the questionnaire. Percentages based on the number
of participants who took prior MPH in the respective subgroups.</p></fn><fn id="tfn7-ndt-12-1085"><p><bold>Abbreviations:</bold> ADHD, attention-deficit/hyperactivity disorder;
ATX, atomoxetine; GXR, guanfacine extended release; MPH, methylphenidate; RCT,
randomized controlled trial; RWS, randomized-withdrawal study.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4-ndt-12-1085" position="float"><label>Table 4</label><caption><p>Responder analyses at end point for prespecified analyses (LOCF, full-analysis
set)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" valign="top" align="left" colspan="1">Definition of response</th><th rowspan="3" valign="top" align="left" colspan="1">Characteristic</th><th colspan="6" valign="top" align="left" rowspan="1">RCT <hr/></th><th colspan="2" valign="top" align="left" rowspan="1">RWS <hr/></th></tr><tr><th colspan="2" valign="top" align="left" rowspan="1">Placebo (n=111) <hr/></th><th colspan="2" valign="top" align="left" rowspan="1">GXR (n=114) <hr/></th><th colspan="2" valign="top" align="left" rowspan="1">ATX (n=112) <hr/></th><th colspan="2" valign="top" align="left" rowspan="1">GXR (n=503) <hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Prior MPH</th><th valign="top" align="left" rowspan="1" colspan="1">Stimulant-na&#x000ef;ve</th><th valign="top" align="left" rowspan="1" colspan="1">Prior MPH</th><th valign="top" align="left" rowspan="1" colspan="1">Stimulant-na&#x000ef;ve</th><th valign="top" align="left" rowspan="1" colspan="1">Prior MPH</th><th valign="top" align="left" rowspan="1" colspan="1">Stimulant-na&#x000ef;ve</th><th valign="top" align="left" rowspan="1" colspan="1">Prior MPH</th><th valign="top" align="left" rowspan="1" colspan="1">Stimulant-na&#x000ef;ve</th></tr></thead><tbody><tr><td rowspan="3" valign="top" align="left" colspan="1">&#x02265;50% reduction from baseline
in ADHD-RS-IV total score</td><td valign="top" align="left" rowspan="1" colspan="1">Number of participants</td><td valign="top" align="left" rowspan="1" colspan="1">48</td><td valign="top" align="left" rowspan="1" colspan="1">55</td><td valign="top" align="left" rowspan="1" colspan="1">45</td><td valign="top" align="left" rowspan="1" colspan="1">60</td><td valign="top" align="left" rowspan="1" colspan="1">48</td><td valign="top" align="left" rowspan="1" colspan="1">58</td><td valign="top" align="left" rowspan="1" colspan="1">221</td><td valign="top" align="left" rowspan="1" colspan="1">206</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Responders, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">14 (29.2)</td><td valign="top" align="left" rowspan="1" colspan="1">19 (34.5)</td><td valign="top" align="left" rowspan="1" colspan="1">24 (53.3)</td><td valign="top" align="left" rowspan="1" colspan="1">36 (60.0)</td><td valign="top" align="left" rowspan="1" colspan="1">15 (31.3)</td><td valign="top" align="left" rowspan="1" colspan="1">33 (56.9)</td><td valign="top" align="left" rowspan="1" colspan="1">143 (64.7)</td><td valign="top" align="left" rowspan="1" colspan="1">152 (73.8)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Percent change from placebo (95% CI;
<italic>P</italic>-value)</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">24.2 (4.7&#x02013;43.6;
<italic>P</italic>=0.011)</td><td valign="top" align="left" rowspan="1" colspan="1">25.5 (7.8&#x02013;43.1;
<italic>P</italic>=0.003)</td><td valign="top" align="left" rowspan="1" colspan="1">2.1 (&#x02212;16.3 to 20.4;
<italic>P</italic>=0.911)</td><td valign="top" align="left" rowspan="1" colspan="1">22.4 (4.5&#x02013;40.3;
<italic>P</italic>=0.010)</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="3" valign="top" align="left" colspan="1">&#x02265;30% reduction from baseline
in ADHD-RS-IV total score</td><td valign="top" align="left" rowspan="1" colspan="1">Number of participants</td><td valign="top" align="left" rowspan="1" colspan="1">48</td><td valign="top" align="left" rowspan="1" colspan="1">55</td><td valign="top" align="left" rowspan="1" colspan="1">45</td><td valign="top" align="left" rowspan="1" colspan="1">60</td><td valign="top" align="left" rowspan="1" colspan="1">48</td><td valign="top" align="left" rowspan="1" colspan="1">58</td><td valign="top" align="left" rowspan="1" colspan="1">221</td><td valign="top" align="left" rowspan="1" colspan="1">206</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Responders, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">24 (50.0)</td><td valign="top" align="left" rowspan="1" colspan="1">32 (58.2)</td><td valign="top" align="left" rowspan="1" colspan="1">35 (77.8)</td><td valign="top" align="left" rowspan="1" colspan="1">50 (83.3)</td><td valign="top" align="left" rowspan="1" colspan="1">28 (58.3)</td><td valign="top" align="left" rowspan="1" colspan="1">45 (77.6)</td><td valign="top" align="left" rowspan="1" colspan="1">180 (81.4)</td><td valign="top" align="left" rowspan="1" colspan="1">181 (87.9)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Percent change from placebo (95% CI;
<italic>P</italic>-value)</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">27.8 (9.1&#x02013;46.4;
<italic>P</italic>=0.008)</td><td valign="top" align="left" rowspan="1" colspan="1">25.2 (9.1&#x02013;41.2;
<italic>P</italic>&#x0003c;0.001)</td><td valign="top" align="left" rowspan="1" colspan="1">8.3 (&#x02212;11.5 to 28.2;
<italic>P</italic>=0.511)</td><td valign="top" align="left" rowspan="1" colspan="1">19.4 (2.5&#x02013;36.3;
<italic>P</italic>=0.008)</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td></tr></tbody></table><table-wrap-foot><fn id="tfn8-ndt-12-1085"><p><bold>Notes:</bold>
<italic>P</italic>-values based on Cochran&#x02013;Mantel&#x02013;Haenszel
statistic comparing the treatment groups, including country and age-group, as
stratification factors. Not all patients had ADHD-RS-IV total score data
available at end point.</p></fn><fn id="tfn9-ndt-12-1085"><p><bold>Abbreviations:</bold> ADHD-RS-IV, Attention-Deficit/Hyperactivity
Disorder Rating Scale version IV; ATX, atomoxetine; CI, confidence interval;
GXR, guanfacine extended release; LOCF, last observation carried forward; MPH,
methylphenidate; NA, not applicable; RCT, randomized controlled trial; RWS,
randomized-withdrawal study.</p></fn></table-wrap-foot></table-wrap></floats-group></article>